WO2006088478A2 - Methods and reagents for diagnosing hantavirus infection - Google Patents

Abstract

Novel methods and immunodiagnostic test kits for the detection of hantavirus infection are disclosed. The methods and kits employ combinations of recombinant N and/or G1 antigens from at least six different hantavirus serotypes, including Hantann (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV). Additional hantavirus antigens from these and other hantavirus types may also be present. The methods provide for highly accurate results and allow the detection of infection so that treatment can be administered and death avoided.

Description

METHODS AND REAGENTS FOR DIAGNOSING HANTAVIRUS INFECTION

CROSS-REFERENCE TO RELATED APPLICATION

This application claims benefit under 35 U.S. C. § 119(e) of provisional application 60/581,027 filed on June 18, 2004, which application is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with support under NIH Grant UOl AIO54779, from the National Institute of Allergy and Infectious Diseases. Accordingly, the United States Government may have certain rights in this invention

TECHNICAL FIELD

The present invention pertains generally to hantaviruses. In particular, the invention relates to immunogenic reagents derived from multiple hantavirus serotypes, including immunogenic nucleocapsid and glycoprotein polypeptides, for use in compositions for diagnosis of hantavirus infection.

BACKGROUND

Hantaviruses (Bunyaviridae: Hantavirus) are lipid-enveloped, minus-sense RNA viruses. The RNA of the viral genome is tripartite, consisting of three fragments generally designated as S, M and L for small, medium and large genome fragments, respectively. The M segment encodes a precursor protein that is processed to form the two envelope glycoproteins, termed Gl and G2. The S segment encodes a nucleocapsid protein, termed N which forms the filamentous helical nucleocapsid of the virus and elicits the humoral response. The L segment of the genome encodes an RNA-dependent RNA polymerase (RDRP). Over 20 distinct hantaviruses are found in association with specific rodent or insectivore hosts worldwide. Their modes of transmission to humans, natural reservoirs, and the clinical features of human infection have been reviewed (see, e.g., Mertz et al., Adv. Internal Med. (1997) 42:369-421). Hantavirus pulmonary syndrome (HPS), also known as hantavirus cardiopulmonary syndrome (HCPS) is an acute febrile illness with up to a 50% mortality rate. Patients present with nonspecific symptoms and progress rapidly to fulminant pulmonary edema and cardiovascular collapse. The predominant agent of HPS in North America is Sin Nombre virus (SNV; also known as Four Corners virus and Muerto Canyon virus). (Song et al., Lancet (1994) 344:1637; Khan et al., J. Med. Virol (1995) 46:281-286; Kahn et al., Am. J. Med. (1996) 100:46-48; Morzunov et al., J. Virol (1995) 69:1980-1983; Rollin et al., J. Med. Virol (1995) 46:35-39; Centers for Disease Control and Prevention, Morbid. Mortal. Weekly Rep. (1993) 43:45-48). At least three other hantaviruses have been associated with HPS in North America, including New York virus (NYV), Black Creek Canal virus (BCCV) and Bayou virus (BAYV).

Worldwide, a larger toll of illness is caused by the Eurasian hantaviruses that cause hemorrhagic fever with renal syndrome (HFRS). HFRS -associated viruses include Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), and Dobrava-Belgrade (DOBV) viruses (Lee et al., J. Infect. Dis. (1978) 137:298-308; Lee, et al., J. Infect. Dis. (1982) 146:638-644; Lee et al., J. Infect. Dis. (1982) 146:645-651; Brummer- Korvenkontio et al., J. Infect. Dis. (1980) 141:131-134). Clinical manifestations of HFRS are generally most severe for HTNV and DOBV infections, whereas PUUV infection is associated with a milder form of HFRS, nephropathia epidemica (NE), occurring in Scandinavia, Finland, Western Russia and Central Europe. Mortality rates of up to 20% have been reported from the most severe forms of HFRS.

Among the HFRS-associated hantaviruses, HTNV, SEOV and DOBV are antigenically similar. The HPS-associated viruses are also closely related to one another, and cross-react with PUUV. Antigenic cross-reactivity is most pronounced among the viral N proteins. In recombinant antigen diagnostic assays, the viral N antigen is dominant over the viral glycoproteins. Antibodies to the N antigen arise early in the course of infection and are universally detectable in convalescence. All persons with acute SNV infection have detectable antibodies against the SNV N antigen of the IgM class by the onset of clinical symptoms, and almost all have IgG antibodies directed against the N and Gl antigens (Bharadwaj et al., J Infect. Dis. (2000) 182:43-48). SNV Gl antibodies are not reactive with the Gl antigens of other hantaviruses (Jenison et al., J. Virol. (1994) 68:3000-3006; Hjelle et al, J. Gen. Virol. (1994) 75:2881-2888).

Hantaviruses are transmitted to humans via inhalation of virus-contaminated aerosols of rodent saliva, urine and feces. A worker can contract hantavirus infection merely by entering into a room with infected rodents, which strongly supports the prevailing view that hantaviruses are transmitted through the air. This observation is also supported by a recent epidemiologic investigation showing that indoor exposures are extremely common. Person-to-person transmission has been demonstrated for the Andes virus (ANDV) in Argentina and is likely to be responsible for two family clusters in Chile. The virus may also be transmitted after rodent bites and possibly through ingestion of contaminated food or water.

All species of hantavirus appear to be primarily associated with a specific rodent host. There are three broad groups of hantaviruses and they are associated with the rodent subfamilies of Murinae, Arvicolinae and Sigmondontinae. The phylogenetic relations among rodents in these various subfamilies parallel, for the most part, the phylogenetic and antigenic relations of viruses associated with each particular reservoir. Each of these groups of hantaviruses contains one or more species or types that are known human pathogens. Information concerning the various hantaviruses is presented in Table 1.

Table 1.

Significant strides have been made in the management of hantavirus infection, but successful management requires that patients be diagnosed before the immediate preagonal stage of illness. Advances in tertiary care management have occurred that may reduce mortality due to hantavirus infection. However, since infection progresses very rapidly, these advances are likely to affect the prognosis only of those patients for whom a diagnosis can be made in a timely manner. A method for rapid detection of hantavirus antibodies appropriate for a rural setting and that could be applied during the early stages of illness could improve the prospects for early intervention.

Several assays have been attempted for the timely diagnosis of hantavirus infection. For example, a variety of formats for serologic diagnosis of hantavirus infection have been employed including bead agglutination, immunofluorescence and immunoprecipitation assays using laboratory-cultivated viruses, hemagglutination inhibition, plaque- and focus-reduction neutralization assays, and ELISA formats (Lee et al., J. Infect. Dis. (1978) 137:298-308; Lee et al., J. Infect. Dis. (1982) 146:638- 644; Lee et al., J. Infect. Dis. (1982) 146:645-651; Lundkvist et al., Clin. Diagnos. Lab. Immunol. (1995) 2:82-86; Chu et al., Virology (1994) 198:196-204; Elgh et al., J. Med. Virol (1995) 45:146-150).

Strip immunoblot assays have also been used in an attempt at efficient diagnosis of hantavirus infection (see, e.g., Hjelle et al., J. Clin. Microbiol. (1997) 35:600-608; Bharadwaj et al., J. Infect. Dis. (2000) 182:43-48; Yee, et al., J. Wildl. Dis. (2003) 39:271-277). However, a universal assay for identifying multiple strains of hantaviruses is not currently available.

The wide-spread availability of an accurate, efficient and rapid assay for hantavirus infection would be highly desirable and could save a considerable number of lives.

SUMMARY OF THE INVENTION

The present invention provides a simple, accurate and efficient method for diagnosing hantavirus infection, as well as for determining the type of hantavirus present. The methods allow the rapid detection, e.g., in less than one hour, of hantavirus infection caused by several hantaviruses, such as hantaviruses from more than one hantavirus serotype. If infection is detected, the individual can be given appropriate treatment in adequate time to prevent death. The method utilizes N and/or Gl antigens and/or antibodies directed against these antigens from at least six different hantavirus serotypes, including HTNV, PUUV, SEOV, DOBV, SNV and ANDV. The assays provide a rapid and reliable diagnostic test and are suitable for use in facilities with relatively unsophisticated laboratory capabilities. Moreover, the assays can be used to screen wild rodents for hantavirus infection in order to determine if a particular rodent population is infected with the virus, thereby preventing infection in laboratory workers, field crews and others who work with and encounter wild rodents.

Recombinant techniques can be used to produce the products described herein to provide protein preparations devoid of other molecules normally present, such as other viral contaminants and harmful proteins. Accordingly, in one embodiment, the invention is directed to a method of detecting hantavirus antibodies in a biological sample. The method comprises:

(a) contacting the biological sample with at least six hantavirus recombinant antigens, wherein the at least six hantavirus recombinant antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV) wherein at least one recombinant antigen from each of the serotypes is present, the contacting performed under conditions which allow hantavirus antibodies, when present in the biological sample, to bind to at least one of the Gl or N antigens to form an antibody/antigen complex; and

(b) detecting the presence or absence of the antibody/antigen complex, thereby detecting the presence or absence of hantavirus antibodies in the sample. The at least six hantavirus recombinant antigens can be any combination of Gl and N antigens as long as at least one antigen from at least six hantavirus serotypes, viz. Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV), is present. In a preferred embodiment, the at least six hantavirus recombinant antigens are all N antigens. In additional embodiments, the invention is directed to an immunodiagnostic test kit for detecting hantavirus infection. The test kit comprises:

(a) at least six hantavirus recombinant antigens, wherein the at least six hantavirus recombinant antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV) wherein at least one antigen from each of the serotypes is present;

(b) and instructions for conducting the immunodiagnostic test.

In a preferred embodiment, the at least six hantavirus recombinant antigens are all N antigens. In further embodiments, the invention is directed to a method of detecting hantavirus antigens in a biological sample. The method comprises:

(a) contacting the biological sample with at least six different antibodies, wherein each of said antibodies is specific for at least one of six hantavirus antigens, wherein the six hantavirus antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV), wherein at least one antibody specific for at least one antigen from each of the serotypes is present, wherein the contacting is done under conditions which allow hantavirus antigens, when present in the biological sample, to bind to the antibodies to form an antibody/antigen complex; and

(b) detecting the presence or absence of the antibody/antigen complex, thereby detecting the presence or absence of hantavirus antigens in the sample. In certain embodiments of the above method, the antibodies are monoclonal antibodies.

In yet an additional embodiment, the invention is directed to an immunodiagnostic test kit for detecting hantavirus infection. The test kit comprises: (a) at least six different antibodies, wherein each of the antibodies is specific for at least one of six hantavirus antigens, wherein the six hantavirus antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV), wherein at least one antibody specific for at least one antigen from each of the serotypes is present; and

(b) instructions for conducting the immunodiagnostic test.

In certain embodiments of the above immunodiagnostic test kit, the antibodies are monoclonal antibodies.

In additional embodiments, the invention is directed to a solid support comprising at least six hantavirus recombinant antigens, wherein the at least six hantavirus recombinant antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV) wherein at least one antigen from each of the serotypes is present. The solid support can be a nitrocellulose strip.

In certain embodiments, the solid support further comprises at least one anti- human immunoglobulin antibody, such one or more antibodies selected from the group consisting of an anti-human IgM antibody, an anti-human IgG antibody and an anti-human IgA antibody, wherein the hantavirus antigens and the anti-human immunoglobulin antibody are immobilized in discrete positions on the solid support.

In additional embodiments, the solid support further comprises at least two internal controls, wherein one of the controls defines the lower detection limit for a positive result in an immunoassay using the solid support and the other control defines a highly positive result in an immunoassay using the solid support. In further embodiments, the invention is directed to an immunodiagnostic test kit for detecting hantavirus. The test kit comprises:

(a) a solid support as described above; and

(b) instructions for conducting the immunodiagnostic test. In additional embodiments, the invention is directed to a method of detecting the presence of hantavirus antibodies in a biological sample. The method comprises:

(a) providing a biological sample;

(b) providing a solid support as described above; (c) contacting the biological sample with the solid support, under conditions which allow hantavirus antibodies, if present in the biological sample, to bind with at least one of the hantavirus antigens to form an antibody/antigen complex; and

(d) detecting the presence of the antibody/antigen complex, thereby detecting the presence of hantavirus antibodies in the biological sample. In certain embodiments, the method above further comprises:

(e) removing unbound hantavirus antibodies;

(f) providing one or more moieties capable of associating with the antibody/antigen complex; and

(g) detecting the presence of the one or more moieties, thereby detecting the presence of hantavirus antibodies in the biological sample. In certain embodiments, the one or more moieties comprises a detectably labeled hantavirus antigen. In these and other embodiments, the detectable label can be an enzyme.

In yet an additional embodiment, the invention is directed to a method of preparing a blood supply comprising whole blood, platelets, plasma or serum, substantially free of hantavirus. The method comprises:

(a) screening aliquots of whole blood, platelets, plasma or serum from collected blood samples by the method of any one of the methods described above;

(b) eliminating any samples in which a hantavirus antigen or a hantavirus antibody is detected; and

(c) combining samples in which neither a hantavirus antigen or a hantavirus antibody is detected to provide a blood supply substantially free of hantavirus.

In any of the methods above, the biological sample can be from a human blood sample. Additionally, In any of the embodiments above, the Gl antigen(s) can comprise an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:40. The Gl antigen(s) can be one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ E⁾ NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47.

Additionally, the N antigen(s) can comprise an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39. In other embodiments, the N antigen(s) can be one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.

The Gl antigen(s) can comprise an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:40 and the N antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39. In additional embodiments, the Gl antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47, and the N antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34 and SEQ ID NO:36.

In additional embodiments, at least one Gl antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV, and at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV.

In further embodiments, at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV. These and other embodiments of the subject invention will readily occur to those of skill in the art in view of the disclosure herein.

BRIEF DESCRIPTION OF THE FIGURES

Figures IA and IB (SEQ ID NOS :1 and 2) show a representative nucleotide sequence for the full-length M segment of HTNV isolate 76-118, encoding the Gl and G2 envelope proteins (Figure IA) and the corresponding amino acid sequence for the Gl protein (Figure IB).

Figures 2A and 2B (SEQ ID NOS: 3 and 4) show a representative nucleotide sequence for the full-length M segment of PUUV isolate CGl 820, encoding the Gl and G2 envelope proteins (Figure 2A) and the corresponding amino acid sequence for the Gl protein (Figure 2B). Figures 3A and 3B (SEQ ID NOS:5 and 6) show a representative nucleotide sequence for the full-length M segment of SEOV isolate 80-39, encoding the Gl and G2 envelope proteins (Figure 3A) and the corresponding amino acid sequence for the Gl protein (Figure 3B).

Figures 4A and 4B (SEQ ID NOS :7 and 8) show a representative nucleotide sequence for the full-length M segment of DOBV, encoding the Gl and G2 envelope proteins (Figure 4A) and the corresponding amino acid sequence for the Gl protein (Figure 4B).

Figures 5 A and 5B (SEQ ID NOS: 9 and 10) show a representative nucleotide sequence for the full-length M segment of SNV isolate NM HlO, encoding the Gl and G2 envelope proteins (Figure 5A) and the corresponding amino acid sequence for the Gl protein (Figure 5B).

Figures 6 A and 6B (SEQ ID NOS: 11 and 12) show a representative nucleotide sequence for the full-length M segment of ANDV isolate Chile-9717869, encoding the Gl and G2 envelope proteins (Figure 6A) and the corresponding amino acid sequence for the Gl protein (Figure 6B).

Figures 7 A and 7B (SEQ ID NOS: 13 and 14) show the nucleotide sequence (Figure 7A) and the corresponding amino acid sequence (Figure 7B) of a representative HTNV Gl peptide for use in the subject assays.

Figures 8 A and 8B (SEQ ID NOS: 15 and 16) show the nucleotide sequence (Figure 8A) and the corresponding amino acid sequence (Figure 8B) of a representative PUUV Gl peptide for use in the subject assays. Figures 9A and 9B (SEQ ID NOS: 17 and 18) show the nucleotide sequence (Figure 9A) and the corresponding amino acid sequence (Figure 9B) of a representative SEOV Gl peptide for use in the subject assays.

Figures 1OA and 1OB (SEQ ID NOS: 19 and 20) show the nucleotide sequence (Figure 10A) and the corresponding amino acid sequence (Figure 10B) of a representative DOBV Gl peptide for use in the subject assays.

Figures 1 IA and 1 IB (SEQ ID NOS:21 and 22) show the nucleotide sequence (Figure 1 IA) and the corresponding amino acid sequence (Figure 1 IB) of a representative SNV Gl peptide for use in the subject assays. Figures 12A and 12B (SEQ ID NOS:23 and 24) show the nucleotide sequence

(Figure 12A) and the corresponding amino acid sequence (Figure 12B) of a representative ANDV Gl peptide for use in the subject assays.

Figures 13A and 13B (SEQ ID NOS :25 and 26) show a representative nucleotide sequence (Figure 13A) and the corresponding amino acid sequence (Figure 13B) of a full-length HTNV N from isolate 76- 118 for use in the subject assays.

Figures 14A and 14B (SEQ ID NOS:27 and 28) show a representative nucleotide sequence (Figure 14A) and the corresponding amino acid sequence (Figure 14B) of a full-length PUUV N from isolate CGl 820 for use in the subject assays.

Figures 15A and 15B (SEQ ID NOS :29 and 30) show a representative nucleotide sequence (Figure 15A) and the corresponding amino acid sequence (Figure 15B) of a full-length SEOV N from isolate 80-39 for use in the subject assays.

Figures 16A and 16B (SEQ ID NOS :31 and 32) show a representative nucleotide sequence (Figure 16A) and the corresponding amino acid sequence (Figure 16B) of a full-length DOBV N for use in the subject assays. Figures 17A and 17B (SEQ ID NOS:33 and 34) show a representative nucleotide sequence (Figure 17A) and the corresponding amino acid sequence (Figure 17B) of a full-length SNV N from isolate NM HlO for use in the subject assays.

Figures 18A and 18B (SEQ ID NOS:35 and 36) show a representative nucleotide sequence (Figure 18A) and corresponding amino acid sequence (Figure 18B) of a full-length ANDV N from isolate Chile-9717869 for use in the subject assays.

Figures 19A and 19B (SEQ ID NOS:37 and 38) show a representative human SOD nucleotide and amino acid sequence, respectively, used in the SOD fusions with the Gl and N antigens, described in the examples. The fused SOD sequence includes amino acids 1-158 of Figure 19B (nucleotides 1-489 of Figure 19A) which includes five amino acids of non-SOD sequence on the C-terminus (TRQNK, SEQ ID NO:41) in order to provide a restriction site for cloning. Figure 20 (SEQ ID NO:42) shows the amino acid sequence of a representative

SOD/HTNV Gl fusion for use in the subject assays.

Figure 21 (SEQ ID NO:43) shows the amino acid sequence of a representative SOD/PUUV Gl fusion for use in the subject assays.

Figure 22 (SEQ ID NO:44) shows the amino acid sequence of a representative SOD/SEOV Gl fusion for use in the subject assays.

Figure 23 (SEQ ID NO:45) shows the amino acid sequence of a representative SOD/DOBV Gl fusion for use in the subject assays.

Figure 24 (SEQ ID NO:46) shows the amino acid sequence of a representative SOD/SNV Gl fusion for use in the subject assays. Figure 25 (SEQ ID NO:47) shows the amino acid sequence of a representative

SOD/ ANDV Gl fusion for use in the subject assays.

Figure 26 (SEQ ID NO:48) shows the amino acid sequence of a representative SOD/HTNV N fusion for use in the subject assays.

Figure 27 (SEQ ID NO:49) shows the amino acid sequence of a representative SOD/PUUV N fusion for use in the subject assays.

Figure 28 (SEQ ID NO:50) shows the amino acid sequence of a representative SOD/SEOV N fusion for use in the subject assays.

Figure 29 (SEQ ID NO: 51) shows the amino acid sequence of a representative SOD/DOBV N fusion for use in the subject assays. Figure 30 (SEQ ID NO:52) shows the amino acid sequence of a representative

SOD/SNV N fusion for use in the subject assays.

Figure 31 (SEQ ID NO: 53) shows the amino acid sequence of a representative S OD/ ANDV N fusion for use in the subject assays.

DETAILED DESCRIPTION OF THE INVENTION

The practice of the present invention will employ, unless otherwise indicated, conventional methods of virology, chemistry, biochemistry, recombinant DNA techniques and immunology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Fundamental Virology, 3rd Edition, vol. I & II (B.N.

Fields and D.M. Knipe, eds.); Handbook of Experimental Immunology, VoIs. I-IV

(D.M. Weir and CC. Blackwell eds., Blackwell Scientific Publications); T.E.

Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A.L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition,

1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press,

Inc.).

All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entireties.

The following amino acid abbreviations are used throughout the text: Alanine: Ala (A) Arginine: Arg (R)

Asparagine: Asn (N) Aspartic acid: Asp (D)

Cysteine: Cys (C) Glutamine: GIn (Q)

Glutamic acid: GIu (E) Glycine: GIy (G)

Histidine: His (H) Isoleucine: He (I)

Leucine: Leu (L) Lysine: Ly s (K)

Methionine: Met (M) Phenylalanine: Phe (F)

Proline: Pro (P) Serine: Ser (S)

Threonine: Thr (T) Tryptophan: Trp (W)

Tyrosine: Tyr (Y) Valine: VaI (V)

I. DEFINITIONS In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

It must be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a Gl polypeptide" includes a mixture of two or more such polypeptides, and the like.

The terms "polypeptide" and "protein" refer to a polymer of amino acid residues and are not limited to a minimum length of the product. Thus, peptides, oligopeptides, dimers, multimers, and the like, are included within the definition. Both full-length proteins and fragments thereof are encompassed by the definition. The terms also include postexpression modifications of the polypeptide, for example, glycosylation, acetylation, phosphorylation and the like. Furthermore, for purposes of the present invention, a "polypeptide" refers to a protein which includes modifications, such as deletions, additions and substitutions (generally conservative in nature), to the native sequence, so long as the protein maintains the desired activity. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the proteins or errors due to PCR amplification.

The term "antigen" when used with reference to the various hantavirus polypeptides for use with the present invention, refers to an N, Gl , etc., polypeptide, whether native, recombinant or synthetic, which includes one or more epitopes that recognize hantavirus antibodies and which are derived from any of the various isolates of the hantavirus strain in question. Accordingly, a "hantavirus antigen" is an antigen derived from any of the hantavirus serotypes, strains and isolates, including, without limitation, any of the various isolates of the Murinae, Sigmodontinae and Arvicolinae subfamilies. For example, an SNV antigen will be derived from any of the various Sin Nombre virus isolates, such as the prototype New Mexico SNV isolate, 3H226, California isolates, British Columbia isolates, etc. Similarly, an

SEOV antigen will be derived from any of the various Seoul virus isolates, and so on. Additional antigens for use in the present invention can be derived from other HPS- and HFRS-associated hantaviruses, including, but not limited to, Sin Nombre virus (SNV; also known as Four Corners virus and Muerto Canyon virus); Andes virus (ANDV); New York virus (NYV); Black Creek Canal virus (BCCV); Bayou virus (BAYV); Hantaan virus (HTNV), Puumala virus (PUUV), Seoul virus (SEOV), and Dobrava-Belgrade (DOBV) virus. The genomic sequences for these viruses are known and several antigenic sequences for use with the present invention are detailed further below. The antigen in question need not include the full-length amino acid sequence of the reference molecule but can include only so much of the molecule as necessary in order for the polypeptide to react with the appropriate hantavirus antibodies. Thus, only one or few epitopes of the reference molecule need be present. Furthermore, the antigen may comprise a fusion protein between the full-length reference molecule or a fragment of the reference molecule, and another protein such as another hantavirus antigen and/or a protein that does not disrupt the reactivity of the hantavirus antigen. It is readily apparent that the antigen may therefore comprise the full-length sequence, fragments, truncated and partial sequences, as well as analogs, muteins and precursor forms of the reference molecule. The term also intends deletions, additions and substitutions to the reference sequence, so long as the antigen retains the ability to react with hantavirus antibodies.

In this regard, natural variation will occur from isolate to isolate within a particular hantavirus strain. Thus, the term is intended to encompass such variation and, in particular, an antigen that varies in its amino acid composition by not more than about 20 number percent, more preferably by not more than about 10 to 15 number percent, and most preferably, by not more than about 5 number percent, from the reference antigen. Proteins having substantially the same amino acid sequence as the reference molecule, but possessing minor amino acid substitutions that do not substantially affect the antibody binding capabilities of the antigen, are therefore within the definition of the reference polypeptide.

An antigen "derived from" a hantavirus serotype, strain or isolate intends an antigen which comprises a sequence of an antigen encoded by the reference hantavirus genome. Typically, the antigen includes one or more epitopes, and will generally have an amino acid sequence substantially homologous to the reference polypeptide, as defined below. Thus, the term "derived from" is used to identify the original source of a molecule but is not meant to limit the method by which the molecule is made which can be, for example, by chemical synthesis or recombinant means.

The terms "analog" and "mutein" refer to biologically active derivatives of the reference molecule, that retain desired activity, such as immunoreactivity in assays described herein. In general, the term "analog" refers to compounds having a native polypeptide sequence and structure with one or more amino acid additions, substitutions (generally conservative in nature) and/or deletions, relative to the native molecule, so long as the modifications do not destroy immunogenic activity and which are "substantially homologous" to the reference molecule as defined below. A number of conserved and variable regions are known between the various isolates and, in general, the amino acid sequences of epitopes derived from these regions will have a high degree of sequence homology, e.g., amino acid sequence homology of more than 50%, generally more than 60%-70%, when the two sequences are aligned. The term "mutein" refers to peptides having one or more peptide mimics ("peptoids"). Preferably, the analog or mutein has at least the same immunoreactivity as the native molecule. Methods for making polypeptide analogs and muteins are known in the art and are described further below.

The terms "analog" and "mutein" also encompasses purposeful mutations that are made to the reference molecule. Particularly preferred analogs include substitutions that are conservative in nature, i.e., those substitutions that take place within a family of amino acids that are related in their side chains. Specifically, amino acids are generally divided into four families: (1) acidic — aspartate and glutamate; (2) basic — lysine, arginine, histidine; (3) non-polar — alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar — glycine, asparagine, glutamine, cysteine, serine threonine, tyrosine.

Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. For example, it is reasonably predictable that an isolated replacement of leucine with isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid, will not have a major effect on the biological activity. For example, the antigen of interest may include up to about 5-10 conservative or non-conservative amino acid substitutions, or even up to about 15-25, 50 or 75 conservative or non-conservative amino acid substitutions, or any integer between 5-75, so long as the desired function of the molecule remains intact. One of skill in the art can readily determine regions of the molecule of interest that can tolerate change by reference to Hopp/Woods and Kyte-Doolittle plots, well known in the art.

By "fragment" is intended an antigen consisting of only a part of the intact full-length polypeptide sequence and structure. The fragment can include a C-terminal deletion an N-terminal deletion, and/or an internal deletion of the native polypeptide. Representative Gl fragments for use in the present assays are shown in Figures 7-12 herein. By "immunogenic fragment" is meant a fragment of a hantavirus polypeptide that includes one or more epitopes and thus elicits one or more of the immunological responses described herein. An "immunogenic fragment" of a particular hantavirus protein will generally include at least about 5-10 contiguous amino acid residues of the full-length molecule, preferably at least about 15-25 contiguous amino acid residues of the full-length molecule, and most preferably at least about 20-50 or more contiguous amino acid residues of the full-length molecule, that define an epitope, or any integer between 5 amino acids and the full-length sequence, provided that the fragment in question retains the ability to elicit an immunological response as defined herein.

By "N antigen" is meant an antigen, as defined above, that is derived from the nucleocapsid protein of the hantavirus in question. The DNA and corresponding amino acid sequences for various hantavirus N proteins are known. For example, the nucleotide sequence and corresponding amino acid sequence for representative N antigens from HTNV, PUUV, SEOV, DOBV, SNV and ANDV are shown in Figures 13-18, respectively. Additionally, the S segments encoding the N proteins of a large number of isolates have been deposited with GenBank and are described further below. Additional sequences are described in International Publication No. WO 95/00648, published January 5, 1995. Hjelle, et al., J. Virol (1994) 68:592-596 describes the amino acid sequences of N antigens derived from SNV, Prospect Hill Virus (PHV) and PUUV.

As explained above, N antigens for use in the present assays include the full- length or substantially full-length proteins, as well as fragments, fusions or mutants of the proteins, which include one or more epitopes such that reactivity with antibodies present in a biological sample from an individual with the particular hantavirus infection in question is retained. For example, N antigens for use in the assays described herein may be a recombinant fusion between the full-length SNV N sequence with another protein, such as another hantavirus antigen, and/or a fusion with a protein that aids in recombinant expression, such as with a 50 kDa E. coli maltose binding protein, or a human or yeast superoxide dismutase (SOD) protein. A representative immunoreactive fragment of the N protein useful in the present assays is a 43 amino acid amino terminal-proximal segment corresponding to the sequence of amino acids found at positions 17-59 of the N polypeptide, numbered relative to SNV NM 10 and having the amino acid sequence

QLVTARQKLKDAERAVELDPDDVNKSTLQSRRAAVSALETKLG (SEQ ID NO: 39). This fragment includes an immunodominant epitope of the N protein and antibodies directed against this epitope are cross-reactive with N proteins from PUUV, SEOV and HTNV (see, e.g., Yamada et al., J. Virol. (1995) 69:1939-1943; and International Publication No. WO 95/06250, published March 2, 1995). Thus, this fragment, as well as larger fragments including this sequence, will find use in the assays herein. For descriptions of epitopes of the N protein see, also, Lundkvist et al., Clin. Diag. Lab. Immunol. (1995) 2:82-86; and Gott et al., Virus Res. (1991) 19:1-16.

By "Gl antigen" is meant an antigen, as defined above, that is derived from the envelope glycoprotein known as Gl, of the hantavirus in question. The DNA and corresponding amino acid sequences for various hantavirus Gl proteins are known. Representative Gl regions are shown in Figures 1-6 herein. Additionally, the M segments, encoding the Gl proteins from a number of isolates have been deposited with GenBank and are described further below. As explained above, Gl antigens for use in the present assays include the full-length or substantially full-length proteins, as well as fragments, fusions or mutants of the proteins, which include one or more epitopes such that reactivity with antibodies present in a biological sample from an individual with the particular hantavirus infection in question is retained. Gl antigens used in the assays described herein include fusions between the Gl antigen in question and a human superoxide dismutase (SOD) sequence shown in Figure 19, to facilitate recombinant expression of the antigen. A number of additional representative immunoreactive fragments of the Gl protein from a number of hantavirus serotypes are shown in Figures 7-12 herein. Another representative immunoreactive fragment of the Gl protein is a 31 amino acid peptide mapped to a segment between amino acids 59 and 89, numbered relative to SNV NM HlO and having the amino acid sequence LKIESSCNFDLHVPATTTQKYNQVDWTKKSS (SEQ ID NO:40). This portion of the Gl protein constitutes an immunoreactive linear epitope recognized by SNV antibodies from various SNV isolates (Jenison et al., J. Virol. (1994) 68:3000-3006). This fragment, as well as larger fragments including this sequence, will find use in the assays herein.

By "immunogenic" sequence of a hantavirus antigen is meant a molecule that includes an amino acid sequence with at least one hantavirus epitope such that the molecule is capable of reacting with antibodies directed against the hantavirus in question, as well as stimulating the production of antibodies in an appropriate host. By "epitope" is meant a site on an antigen to which specific B cells and/or T cells respond, rendering the hantavirus epitope in question capable of reacting with hantavirus antibodies present in a biological sample, as well as stimulating antibody production. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site." An epitope can comprise 3 or more amino acids in a spatial conformation unique to the epitope. Generally, an epitope consists of at least 5 such amino acids and, more usually, consists of at least 8-10 such amino acids or more.

Regions of a given polypeptide that include an epitope can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, New Jersey. For example, linear epitopes may be determined by e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Patent No. 4,708,871; Geysen et al. (1984) Proc. Natl. Acad. Sd. USA 81:3998-4002; Geysen et al. (1985) Proc. Natl. Acad. ScL USA 82:178-182; Geysen et al. (1986) Mo/ec. Immunol. 23_:709-715, all incorporated herein by reference in their entireties. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and

2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra. Antigenic regions of proteins can also be identified using standard antigenicity and hydropathy plots, such as those calculated using, e.g., the Omiga version 1.0 software program available from the Oxford Molecular Group. This computer program employs the Hopp/Woods method, Hopp et al., Proc. Natl. Acad. Sd USA (1981) 78:3824-3828 for determining antigenicity profiles, and the Kyte-Doolittle technique, Kyte et al., J. MoI. Biol. (1982) 157:105-132 for hydropathy plots.

An "immunogenic composition" is a composition that comprises at least one immunogenic polypeptide (e.g., an N and/or Gl hantavirus antigen). "Substantially purified" generally refers to isolation of a substance

(compound, polynucleotide, protein, polypeptide, polypeptide composition) such that the substance comprises the majority percent of the sample in which it resides. Typically in a sample a substantially purified component comprises 50%, preferably 80%-85%, more preferably 90-95% of the sample. Techniques for purifying polynucleotides and polypeptides of interest are well-known in the art and include, for example, ion-exchange chromatography, affinity chromatography and sedimentation according to density. By "isolated" is meant, when referring to a polypeptide, that the indicated molecule is separate and discrete from the whole organism with which the molecule is found in nature or is present in the substantial absence of other biological macro-molecules of the same type. The term "isolated" with respect to a polynucleotide is a nucleic acid molecule devoid, in whole or part, of sequences normally associated with it in nature; or a sequence, as it exists in nature, hut having heterologous sequences in association therewith; or a molecule disassociated from the chromosome.

By "equivalent antigenic determinant" is meant an antigenic determinant from different isolates or strains of a hantavirus which antigenic determinants are not necessarily identical due to sequence variation, but which occur in equivalent positions in the hantavirus sequence in question. In general the amino acid sequences of equivalent antigenic determinants will have a high degree of sequence homology, e.g., amino acid sequence homology of more than 30%, usually more than 40%, such as more than 60%, and even more than 80-90% homology, when the two sequences are aligned.

"Homology" refers to the percent identity between two polynucleotide or two polypeptide moieties. Two nucleic acid, or two polypeptide sequences are "substantially homologous" to each other when the sequences exhibit at least about 50% , preferably at least about 75%, more preferably at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecules. As used herein, substantially homologous also refers to sequences showing complete identity to the specified sequence.

In general, "identity" refers to an exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence of two polynucleotides or polypeptide sequences, respectively. Percent identity can be determined by a direct comparison of the sequence information between two molecules (the reference sequence and a sequence with unknown % identity to the reference sequence) by aligning the sequences, counting the exact number of matches between the two aligned sequences, dividing by the length of the reference sequence, and multiplying the result by 100. Readily available computer programs can be used to aid in the analysis, such as ALIGN, Dayhoff, M.O. in Atlas of Protein Sequence and Structure M.O. Dayhoff ed., 5 Suppl. 3:353-358, National biomedical Research Foundation, Washington, DC, which adapts the local homology algorithm of Smith and Waterman Advances in Appl Math. 2:482-489, 1981 for peptide analysis. Programs for determining nucleotide sequence identity are available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, WI) for example, the BESTFIT, FASTA and GAP programs, which also rely on the Smith and Waterman algorithm. These programs are readily utilized with the default parameters recommended by the manufacturer and described in the Wisconsin Sequence Analysis Package referred to above. For example, percent identity of a particular nucleotide sequence to a reference sequence can be determined using the homology algorithm of Smith and Waterman with a default scoring table and a gap penalty of six nucleotide positions. Another method of establishing percent identity in the context of the present invention is to use the MPSRCH package of programs copyrighted by the University of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and distributed by IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages the Smith- Waterman algorithm can be employed where default parameters are used for the scoring table (for example, gap open penalty of 12, gap extension penalty of one, and a gap of six). From the data generated the "Match" value reflects "sequence identity." Other suitable programs for calculating the percent identity or similarity between sequences are generally known in the art, for example, another alignment program is BLAST, used with default parameters. For example, BLASTN and

BLASTP can be used using the following default parameters: genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein + Spupdate + PIR. Details of these programs are readily available.

Alternatively, homology can be determined by hybridization of polynucleotides under conditions which form stable duplexes between homologous regions, followed by digestion with single-stranded-specific nuclease(s), and size determination of the digested fragments. DNA sequences that are substantially homologous can be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Sambrook et al., supra; DNA Cloning, supra; Nucleic Acid Hybridization, supra.

"Recombinant" as used herein to describe a nucleic acid molecule means a polynucleotide of genomic, cDNA, viral, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation is not associated with all or a portion of the polynucleotide with which it is associated in nature. The term "recombinant" as used with respect to a protein or polypeptide means a polypeptide produced by expression of a recombinant polynucleotide. In general, the gene of interest is cloned and then expressed in transformed organisms, as described further below. The host organism expresses the foreign gene to produce the protein under expression conditions.

An "antibody" intends a molecule that specifically binds to an epitope of interest present in an antigen. By "specifically binds" is meant that the antibody recognizes and interacts with the epitope in a "lock and key" type of interaction to form a complex between the antigen and antibody, as opposed to non-specific binding that might occur between the antibody and, for instance, the test substrate with which the antibody is reacted. Thus, an anti-hantavirus Gl antibody is a molecule that specifically binds to an epitope of a hantavirus Gl protein. The term "antibody" as used herein includes antibodies obtained from both polyclonal and monoclonal preparations, as well as, the following: hybrid (chimeric) antibody molecules (see, for example, Winter et al., Nature (1991) 349:293-299; and U.S. Patent No. 4,816,567); F(ab')2 and F(ab) fragments; Fv molecules (non-covalent heterodimers, see, for example, Inbar et al., Proc Natl Acad Sd USA (1972) 69:2659-2662; and Ehrlich et al., Biochem (1980) 19:4091-4096); single-chain Fv molecules (sFv) (see, for example, Huston et al., Proc Natl Acad Sd USA (1988) 85:5879-5883); dimeric and trimeric antibody fragment constructs; minibodies (see, e.g., Pack et al., Biochem (1992) 3J,:1579-1584; Cumber et al., J Immunology (1992) M9B: 120-126); humanized antibody molecules (see, for example, Riechmann et al., Nature (1988) 332:323-327; Verhoeyan et al., Science (1988) 239:1534-1536; and U.K. Patent Publication No. GB 2,276,169, published 21 September 1994); and, any functional fragments obtained from such molecules, wherein such fragments retain immunological binding properties of the parent antibody molecule.

As used herein, the term "monoclonal antibody" refers to an antibody composition having a homogeneous antibody population. The term is not limited regarding the species or source of the antibody, nor is it intended to be limited by the manner in which it is made. The term encompasses whole immunoglobulins as well as fragments such as Fab, F(ab')₂, Fv, and other fragments, as well as chimeric and humanized homogeneous antibody populations, that exhibit immunological binding properties of the parent monoclonal antibody molecule. As used herein, a "solid support" refers to a solid surface to which a macromolecule, e.g., protein, polypeptide, peptide, polynucleotide can be attached, such as a magnetic bead, latex bead, microtiter plate well, glass plate, nylon, agarose, polyacrylamide, silica particle, nitrocellulose membrane, and the like.

"Immunologically reactive" means that the antigen in question will react specifically with anti-hantavirus antibodies present in a biological sample from a hantavirus-infected individual.

"Immune complex" intends the combination formed when an antibody binds to an epitope on an antigen.

As used herein, a "biological sample" refers to a sample of tissue or fluid isolated from a subject such as, but not limited to, blood, plasma, serum, fecal matter, urine, bone marrow, bile, spinal fluid, lymph fluid, cerebrospinal fluid, samples of the skin, secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, organs, biopsies and also samples of in vitro cell culture constituents including but not limited to conditioned media resulting from the growth of cells and tissues in culture medium, e.g., recombinant cells, and cell components. The samples detailed above need not necessarily be in the form obtained directly from the source. For example, the sample can be treated prior to use, such as, for example, by heating, centrifuging, etc. prior to analysis.

As used herein, the terms "label" and "detectable label" refer to a molecule capable of detection, including, but not limited to, radioactive isotopes, fluorescers, semiconductor nanocrystals, chemiluminescers, chromophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, , dyes, metal ions, metal sols, ligands (e.g., biotin, strepavidin or haptens) and the like. The term "fluorescer" refers to a substance or a portion thereof which is capable of exhibiting fluorescence in the detectable range. Particular examples of labels which may be used under the invention include, but are not limited to, horse radish peroxidase (HRP), fluorescein, FITC, rhodamine, dansyl, umbelliferone, dimethyl acridinium ester (DMAE), Texas red, luminol, NADPH and α-β-galactosidase.

II. MODES OF CARRYING OUT THE INVENTION

Before describing the present invention in detail, it is to be understood that this invention is not limited to particular formulations or process parameters as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

Although a number of methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred materials and methods are described herein.

The present invention is based on the discovery of novel diagnostic methods for accurately detecting hantavirus infection. The methods utilize hantavirus recombinant N and Gl antigens comprising immunodominant epitopes, and/or antibodies directed against these antigens, from at least six different hantavirus serotypes, including HTNV, PUUV, SEOV, DOBV, SNV and ANDV. In certain embodiments, the assays include, for example, six recombinant Gl antigens (and/or antibodies directed against six Gl antigens), one from each of the above serotypes, and/or six recombinant N antigens, one from each of the above serotypes. In alternative embodiments, the assay can include, for example, at least one recombinant N antigen derived from any one of these six serotypes, that produces antibodies that cross-react with one or more of the other five serotypes, and six recombinant Gl antigens, one from each of the six serotypes. For example, the assays can include an N antigen (and/or antibodies directed against the N antigen) from SNV. The assays will also include Gl antigens (and/or antibodies directed against Gl antigens), preferably from all six of the serotypes HTNV, PUUV, SEOV, DOBV, SNV and

ANDV. Alternatively, the assay can include a Gl antigen (and/or antibodies thereto) from any one of these six serotypes, and six N antigens (and/or antibodies thereto) from each of these six serotypes. In another embodiment, the assay can include, for example, three Gl antigens (and/or antibodies thereto) from three of the six serotypes, and three N antigens (and/or antibodies thereto) from the other three of the six serotypes. Alternatively, the assay can include two Gl antigens (and/or antibodies thereto) and four N antigens (and/or antibodies thereto), or four Gl antigens (and/or antibodies thereto) and two N antigens (and/or antibodies thereto), or one Gl antigen (and/or antibodies thereto) and five N antigens (and/or antibodies thereto), or five Gl antigens (and/or antibodies thereto) and one N antigen (and/or antibodies thereto), or four Gl antigens (and/or antibodies thereto) and four N antigens (and/or antibodies thereto), or five Gl antigens (and/or antibodies thereto and five N antigens (and/or antibodies thereto), and so on. It is readily apparent that any combination of recombinant Gl and N antigens (and/or antibodies thereto) can be used so long as the six serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV are represented. The assays of the present invention can also utilize additional hantavirus antigens, derived from any of the various hantavirus strains described in Table 1 or others subsequently identified.

The use of hantavirus N and/or Gl antigens (and/or antibodies thereto) from the six serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV, optionally in combination with other hantavirus proteins and/or antibodies, allows for the diagnosis of infection caused by any of the various known hantavirus serotypes. Moreover, the assays can be adapted such that the particular hantavirus serotype causing infection can be identified. For example, biological samples from patients infected with a variety of HPS- and HFRS -associated hantaviruses react with SNV N antigens, but not necessarily with SNV Gl antigens. Thus, the presence of reactivity with an SNV N antigen and the absence of reactivity with an SNV Gl antigen, indicates infection with a hantavirus other than SNV, and the like. It is readily apparent that a wide variety of antigens and combinations of antigens (or antibodies directed against these antigens) can be used in the present diagnostic assays.

The methods are useful for detecting hantavirus infection in humans, as well as in rodent populations. The methods can detect hantavirus infection in blood samples, including without limitation, in whole blood, serum and plasma. Thus, the methods can be used to diagnose hantavirus infection in a subject, such as a human or rodent subject, as well as to detect hantavirus contamination in donated blood samples. Aliquots from individual donated samples or pooled samples can be screened for the presence of hantavirus and those samples or pooled samples contaminated with hantavirus can be eliminated before they are combined. In this way, a blood supply substantially free of hantavirus contamination can be provided.

In order to further an understanding of the invention, a more detailed discussion is provided below regarding hantaviruses, as well as various hantavirus antigens and antibodies for use in the subject compositions and methods.

Hantavirus Antigens

As explained above, the hantavirus family of viruses belongs to the Bimyavirus genus and the viruses are enveloped, minus-sense RNA viruses. The RNA of the viral genome is tripartite, consisting of three fragments generally designated as S, M and L for small, medium and large genome fragments, respectively. The M segment encodes two envelope glycoproteins, termed Gl and G2, in a single open reading frame. The S segment encodes the nucleocapsid protein, termed N and the L segment of the genome encodes an RNA-dependent RNA polymerase.

Several distinct hantaviruses are found in association with specific rodent hosts worldwide (see, Table 1). As explained above, N and/or Gl antigens derived from at least six major hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV, will find use herein. Sequences for N and Gl antigens from numerous isolates identified as belonging to these serotypes, and the nucleic acid sequences encoding these antigens, are known. Representative sequences from which Gl antigens can be derived are depicted in Figures 1-12 herein. Although the Gl antigens depicted in the figures include an N-terminal methionine, the Gl peptides for use herein need not include this methionine, especially if produced by synthetic means. The Gl antigens for use herein can include the full-length Gl protein or immunogenic fragments of the Gl protein. Particularly useful are fragments that include at least the region corresponding to the 31 amino acid sequence represented by amino acids 59-89, numbered relative to SNV NM HlO (LKIESSCNFDLHVPATTTQKYNQVDWTKKSS (SEQ ID NO:40). This region of the Gl protein constitutes an immunoreactive linear epitope and is found in each of the Gl immunogenic fragments shown in Figures 7-12 herein. This sequence is not the same in the six hantavirus serotypes of interest herein. Thus, it is to be understood that an amino acid sequence from a non-SNV hantavirus that "corresponds" to this sequence is an amino acid segment from the non-SNV hantavirus that falls in the same region and displays homology to this sequence but does not necessarily show 100% identity to this sequence. The corresponding region in the other five hantavirus serotypes is readily identifiable from a review of Figures 7-12 herein.

Immunogenic Gl antigens comprising a sequence of amino acids corresponding to the sequence of amino acids shown in SEQ ID NO:40 can include, for example, 31 amino acids, up to the full-length of the Gl molecule, such as 31-500 amino acids, preferably 31-250 amino acids, even more preferably 31-150 amino acids, such as 31 to 50...60...70...75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85,

86...90...100...200...300...400...500, up to the full-length Gl molecule, or any integer within these ranges. Moreover, the Gl antigens for use herein may lack all or a portion of the transmembrane binding domain and/or the cytoplasmic tail found in the C-terminus of the envelope. Thus, the present invention contemplates the use of envelope polypeptides which retain the transmembrane binding domain and cytoplasmic tail, as well as antigens which lack all or a portion of the transmembrane binding domain and/or the cytoplasmic tail, as well as adjacent portions of the Gl protein. The location of such domains can be readily determined using computer programs and algorithms well known in the art, such as the Kyte-Doolittle technique, Kyte et al., J. MoI. Biol. (1982) 157:105-132.

Additional sequences from which the Gl antigens can be derived are well known. For example, Gl sequences can be derived from any of the various HTNV sequences such as those sequences deposited with NCBI under accession numbers NC_005219, AF345636, D25532, D25529, D00377, D00376, AF288645, AF366569, AF035831, Y00386, U38177, U37729, M14627 and L08753. Gl sequences can be derived from any of the various SNV sequences such as those sequences deposited with NCBI under accession numbers L37903, , L25783, AF030552, AF030551 and U02471. Gl sequences can be derived from any of the various ANDV sequences such as those sequences deposited with NCBI under accession numbers NC_003467 and AF291703. Gl sequences can be derived from any of the various SEOV sequences such as those sequences deposited with NCBI under accession numbers AF458104, AB027521, AF288654, AF288652, AF288650 and S47716. Gl sequences can be derived from any of the various PUUV sequences such as those sequences deposited with NCBI under accession numbers NC_005223, AY526218, U14136, U22418, L08754, L08755, X61034, X55129 and M29979. Gl sequences can be derived from any of the various DOBV sequences such as those sequences deposited with NCBI under accession numbers NC_005234, AJ410616, AY168578, AY168577 and L33685.

Representative sequences from which N antigens can be derived are depicted in Figures 13-18 herein. As described above for the Gl antigens, the N antigens may or may not include an N-terminal methionine. The N antigens for use herein can include the full-length N protein or immunogenic fragments of the N protein. Particularly useful are fragments that include at least the region corresponding to the 43 amino acid sequence found at positions 17-59 of the N polypeptide, numbered relative to SNV NM HlO

(QLVTARQKLKDAERAVELDPDDVNKSTLQSRRAAVSALETKLG (SEQ ID NO: 39). This region of the N protein includes an immunodominant epitope and antibodies directed against this epitope are cross-reactive with N proteins from PUUV, SEOV and HTNV.

This sequence is not the same in the six hantavirus serotypes of interest herein. Thus, it is to be understood that an amino acid sequence from a non-SNV hantavirus that "corresponds" to this sequence is an amino acid segment from the non-SNV hantavirus that falls in the same region and displays homology to this sequence but does not necessarily show 100% identity to this sequence. The corresponding region in the other five hantavirus serotypes is readily identifiable from a review of Figures 13-18 herein.

Immunogenic N antigens comprising a sequence of amino acids corresponding to the sequence of amino acids shown in SEQ ID NO:39 can include, for example, 43 amino acids, up to the full-length of the N molecule, such as 43-350 amino acids, preferably 43-300 amino acids, more preferably 43-200 amino acids, even more preferably 43-100 amino acids, such as 43 to 60... 70... 80... 90... 100... 200... 300... 400, up to the full-length N molecule, or any integer within these ranges. Additional sequences from which the N antigens can be derived are well known. For example, N sequences can be derived from any of the various HTNV sequences such as those sequences deposited with NCBI under accession numbers AB127998, AB027101, AB027523, AB027097, D25533, AF288646, AF288644, AF427324, AF427323, AF427322, AF427320, AF427319, AF427318, AF366568, AY017064, AF321095, AF321094, AF288296, U37768 and M14626. N sequences can be derived from any of the various SNV sequences such as those sequences deposited with NCBI under accession numbers NC_005216, L37904, L25784, L33816, L33683 and U02474. N sequences can be derived from any of the various ANDV sequences such as those sequences deposited with NCBI under accession numbers NC_003466, AF325966, AF0044660 and AF291702. N sequences can be derived from any of the various SEOV sequences such as those sequences deposited with NCBI under accession numbers NC_005236, AF488708, AF488707, AY273791, AB027522, AF329390, AF288655, AF288653, AF288643, AF406965, AY006465. N sequences can be derived from any of the various PUUV sequences such as those sequences deposited with NCBI under accession numbers NC_005224, AY526219, AJ314601, AJ314600, AJ314599, AJ314598, AJ314597, AF442613, AF367071, AF367070, AF367068, AF367067, AF367066, AF367065, AF367064, AJ277030, AJ277076, AJ277075, AJ277034, AJ277033, AJ277032, AJ277031, AJ238791, AJ238790, AJ238789, AJ238788, X61035, AB010731, AB010730, U14137, AF294652, U22423, L08804, Ll 1347 and M32750. N sequences can be derived from any of the various DOBV sequences such as those sequences deposited with NCBI under accession numbers NC_005233, AJ616854, AJ410619, AJ410615, AJ131673, AJ131672, AJ269550, AJ269549, AJ009775, AJ009773, AY168576 and L41916.

The recombinant N and Gl antigens can be provided as discrete products or as fusions of the various N and Gl antigens, with or without other hantavirus antigens from one of more of these six serotypes, as well as with antigens derived from serotypes in addition to HTNV, PUUV, SEOV, DOBV, SNV and ANDV. By way of example, fusions can comprise Gl antigens from the six serotypes above. This fusion can be used alone or in combination with a second fusion including one or more N antigens from one or more of these six serotypes. Similarly, fusions can comprise N antigens from the six serotypes above and this fusion can be used alone or in combination with a second fusion including one or more Gl antigens from one or more of these six serotypes. Alternatively, all N and Gl antigens can be provided in a single fusion, or multiple fusions. It is readily apparent that fusion proteins of the subject invention can take any number of forms so long as N and/or Gl antigens from HTNV, PUUV, SEOV, DOBV, SNV and ANDV are present. If a fusion is produced, the polypeptides need not be organized in the same order as found in the native virus. Thus, for example, a Gl polypeptide can be fused to the N-terminus or C-terminus of an N polypeptide, etc. Other possible fusion proteins include a fusion of a human or yeast superoxide dismutase (SOD) protein, or fragment of the SOD protein, with a hantavirus Gl and/or N polypeptide. For examples of recombinant proteins expressed as human SOD fusion antigens, see Barr et al., Vaccine (1987) 5_^:90-101; Pichuantes et al., Proteins Struct. Fuct. Genet. (1989) 6:324-327; Pichuantes et al., J. Biol. Chem. (1990) 23:13890-13898.

Antigens for use with the present invention can be obtained using standard techniques. For example, the hantavirus antigens are conveniently generated using recombinant methods, well known in the art. See, e.g., International Publication No. WO 95/00648, published January 5, 1995; International Publication No. WO 95/06240, published March 2,1995; and Hjelle, et al., J. Virol (1994) 68:592-596, for descriptions of the recombinant production of hantavirus antigens. Oligonucleotide probes can be devised based on the known sequences of the hantavirus genome and used to probe genomic or cDNA libraries for hantavirus genes encoding for the antigens useful in the present invention. The genes can then be further isolated using standard techniques and, if desired, restriction enzymes employed to mutate the gene at desired portions of the full-length sequence. Similarly, hantavirus genes can be isolated directly from infected tissue using known techniques, such as by phenol extraction (see, e.g., International Publication No. WO 95/00648, published January 5, 1995), and the sequence can be further manipulated to produce any desired alterations. See, e.g., Sambrook et al., supra, for a description of techniques used to obtain and isolate DNA. Finally, the genes encoding the hantavirus antigens can be produced synthetically, based on the known sequences. The nucleotide sequence can be designed with the appropriate codons for the particular amino acid sequence desired. In general, one will select preferred codons for the intended host in which the sequence will be expressed. The complete sequence is generally assembled from overlapping oligonucleotides prepared by standard methods and assembled into a complete coding sequence. See, e.g., Edge, Nature (1981) 292:756; Nambair et al., Science (1984) 223:1299; Jay et al., J. Biol. Chem. (1984) 259:6311. Polynucleotides can comprise coding sequences for the various polypeptides which occur naturally or can include artificial sequences which do not occur in nature. These polynucleotides can be ligated to form a coding sequence for a fusion protein, if desired, using standard molecular biology techniques. Once coding sequences have been prepared or isolated, such sequences can be cloned into any suitable vector or replicon. Numerous cloning vectors are known to those of skill in the art, and the selection of an appropriate cloning vector is a matter of choice. Suitable vectors include, but are not limited to, plasmids, phages, transposons, cosmids, chromosomes or viruses which are capable of replication when associated with the proper control elements. The coding sequence is then placed under the control of suitable control elements, depending on the system to be used for expression. Thus, the coding sequence can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator, so that the DNA sequence of interest is transcribed into RNA by a suitable transformant. The coding sequence may or may not contain a signal peptide or leader sequence which can later be removed by the host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437; 4,338,397.

If present, the signal sequence can be the native leader found in association with the hantavirus polypeptide of interest. For example, if the hantavirus polypeptide being expressed is a Gl antigen, all or a portion of the native Gl leader sequence can be included. Alternatively, a heterologous signal sequence can be present which can increase the efficiency of secretion. A number of representative leader sequences are known in the art and include, without limitation, the yeast α- factor leader, the TPA signal peptide, the Ig signal peptide, and the like. Sequences for these and other leader sequences are well known in the art.

In addition to control sequences, it may be desirable to add regulatory sequences which allow for regulation of the expression of the sequences relative to the growth of the host cell. Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Other types of regulatory elements may also be present in the vector. For example, enhancer elements may be used herein to increase expression levels of the constructs. Examples include the SV40 early gene enhancer (Dijkema et al. (1985) EMBO J. 4:761), the enhancer/promoter derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus (Gorman et al. (1982) Proc. Natl. Acad. Sci. USA 79:6777) and elements derived from human CMV (Boshart et al. (1985) Cell 41:521), such as elements included in the CMV intron A sequence (U.S. Patent No. 5,688,688). The expression cassette may further include an origin of replication for autonomous replication in a suitable host cell, one or more selectable markers, one or more restriction sites, a potential for high copy number and a strong promoter.

An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence). Modification of the sequences encoding the molecule of interest may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it can be attached to the control sequences in the appropriate orientation; i.e., to maintain the reading frame. The control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector. Alternatively, the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.

As explained above, it may also be desirable to produce mutants or analogs of the polypeptide of interest. Mutants or analogs of hantavirus polypeptides for use in the subject compositions may be prepared by the deletion of a portion of the sequence encoding the molecule of interest, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, and the like, are well known to those skilled in the art. See, e.g., Sambrook et al., supra; Kunkel, T. A. (1985) Proc. Natl. Acad. Sci. USA (1985) 82:448; Geisselsoder et al. (1987) BioTechniques 5:786; Zoller and Smith (1983) Methods Enzymol. 100:468; Dalbie-McFarland et al. (1982) Proc. Natl. Acad. Sci USA 79:6409.

In order to facilitate recombinant expression, the molecule of interest can be expressed as a fusion protein, such as a fusion with, e.g., a 50 kDa E. coli maltose binding protein, a fusion with a human or yeast superoxide dismutase (SOD) or fragment thereof, or as a ubiquitin fusion protein.

The molecules can be expressed in a wide variety of systems, including insect, mammalian, bacterial, viral and yeast expression systems, all well known in the art. For example, insect cell expression systems, such as baculovirus systems, are known to those of skill in the art and described in, e.g., Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987). Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA ("MaxBac" kit). Similarly, bacterial and mammalian cell expression systems are well known in the art and described in, e.g., Sambrook et al., supra. Yeast expression systems are also known in the art and described in, e.g., Yeast Genetic Engineering (Barr et al., eds., 1989) Butterworths, London.

A number of appropriate host cells for use with the above systems are also known. For example, mammalian cell lines are known in the art and include immortalized cell lines available from the American Type Culture Collection (ATCC), such as, but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human embryonic kidney cells, human hepatocellular carcinoma cells (e.g., Hep G2), Madin-Darby bovine kidney ("MDBK") cells, as well as others. Similarly, bacterial hosts such as E. coli, Bacillus subtilis, and Streptococcus spp., will find use with the present expression constructs. Yeast hosts useful in the present invention include inter alia, Saccharomyces cerevisiae, Candida albicans, Candida maltosa, Hansenula polymorpha, Kluyveromyces fragilis, Kluyveromyces lactis, Pichia guillerimondii, Pichia pastoris, Schizosaccharomyces pombe and Yatrowia lipolytica. Insect cells for use with baculovirus expression vectors include, inter alia, Aedes aegypti, Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni.

Nucleic acid molecules comprising nucleotide sequences of interest can be stably integrated into a host cell genome or maintained on a stable episomal element in a suitable host cell using various gene delivery techniques well known in the art. See, e.g., U.S. Patent No. 5,399,346. Depending on the expression system and host selected, the molecules are produced by growing host cells transformed by an expression vector described above under conditions whereby the protein is expressed. The expressed protein is then isolated from the host cells and purified. If the expression system secretes the protein into growth media, the product can be purified directly from the media. If it is not secreted, it can be isolated from cell lysates. The selection of the appropriate growth conditions and recovery methods are within the skill of the art.

The hantavirus antigens are used herein as diagnostics to detect the presence of reactive antibodies directed against the virus in a biological sample. Furthermore, the antigens can be used to determine which hantavirus type is responsible for infection. The antigens may also be used to produce antibodies for use in diagnostics.

Hantavirus Antibodies

The hantavirus antigens can be used to produce hantavirus-specific polyclonal and monoclonal antibodies. Hantavirus-specific polyclonal and monoclonal antibodies specifically bind to hantavirus antigens. Polyclonal antibodies can be produced by administering the hantavirus antigen to a mammal, such as a mouse, a rabbit, a goat, or a horse. Serum from the immunized animal is collected and the antibodies are purified from the plasma by, for example, precipitation with ammonium sulfate, followed by chromatography, preferably affinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art.

Monoclonal antibodies directed against hantavirus-specific epitopes present in the proteins can also be readily produced. Normal B cells from a mammal, such as a mouse (see, e,g., Kohler and Milstein, Nature (1975) 256:495-497), or a rabbit (see, e.g., U.S. Patent No. 5675,063 incorporated herein by reference in its entirety), immunized with a hantavirus antigen, can be fused with, for example, HAT-sensitive mouse myeloma cells to produce hybridomas. Hybridomas producing hantavirus-specific antibodies can be identified using RIA or ELISA and isolated by cloning in semi-solid agar or by limiting dilution. Clones producing hantavirus-specific antibodies are isolated by another round of screening.

It may be desirable to provide chimeric antibodies. Chimeric antibodies composed of human and non-human amino acid sequences may be formed from the mouse monoclonal antibody molecules to reduce their immunogenicity in humans (Winter et al. (1991) Nature 349:293; Lobuglio et al. (1989) Proc. Nat. Acad. ScL USA 86:4220; Shaw et al. (1987) J Immunol. 138:4534; and Brown et al. (1987) Cancer Res. 47:3577; Riechmann et al. (1988) Nature 332:323; Verhoeyen et al. (1988) Science 239:1534; and Jones et al. (1986) Nature 321:522; EP Publication No. 519,596, published 23 December 1992; and U.K. Patent Publication No. GB 2,276,169, published 21 September 1994).

Antibody molecule fragments, e.g., F(ab')2, Fv, and sFv molecules, that are capable of exhibiting immunological binding properties of the parent monoclonal antibody molecule can be produced using known techniques. Inbar et al. (1972) Proc. Nat. Acad. ScL USA 69:2659; Hochman et al. (1976) Biochem 15:2706; Ehrlich et al. (1980) Biochem 19:4091; Huston et al. (1988) Proc. Nat. Acad. ScL USA 85(16):5879; and U.S. Patent Nos. 5,091,513 and 5,132,405, to Huston et al.; and 4,946,778, to Ladner et al.

In the alternative, a phage-display system can be used to expand monoclonal antibody molecule populations in vitro. Saiki, et al. (1986) Nature 324: 163 ; Scharf et al. (1986) Science 233:1076; U.S. Patent Nos. 4,683,195 and 4,683,202; Yang et al. (1995) JMo/ 5ra/ 254:392; Barbas, III et al. (1995) Methods: Comp. Meth Enzymol 8:94; Barbas, III et al. (1991) Proc Natl Acad Sci USA 88:7978.

Once generated, the phage display library can be used to improve the immunological binding affinity of the Fab molecules using known techniques. See, e.g., Figini et al. (1994) J. MoI. Biol. 239:68. The coding sequences for the heavy and light chain portions of the Fab molecules selected from the phage display library can be isolated or synthesized, and cloned into any suitable vector or replicon for expression. Any suitable expression system can be used, including those described above.

Antibodies which are directed against hantavirus epitopes, are particularly useful for detecting the presence of hantavirus or hantavirus antigens in a sample, such as a serum sample from a hantavirus-infected human. An immunoassay for a hantavirus antigen may utilize one antibody or several antibodies either alone or in combination with hantavirus antigens. An immunoassay for a hantavirus antigen may use, for example, a monoclonal antibody directed towards a hantavirus epitope, a combination of monoclonal antibodies directed towards epitopes of one hantavirus polypeptide, monoclonal antibodies directed towards epitopes of different hantavirus polypeptides, polyclonal antibodies directed towards the same hantavirus antigen, polyclonal antibodies directed towards different hantavirus antigens, or a combination of monoclonal and polyclonal antibodies. Immunoassay protocols may be based, for example, upon competition, direct reaction, or sandwich type assays using, for example, labeled antibody and are described further below. The labels may be, for example, fluorescent, chemiluminescent, or radioactive.

The hantavirus antibodies may further be used to isolate hantavirus particles or antigens by immunoaffinity columns. The antibodies can be affixed to a solid support by, for example, adsorption or by covalent linkage so that the antibodies retain their immunoselective activity. Optionally, spacer groups may be included so that the antigen binding site of the antibody remains accessible. The immobilized antibodies can then be used to bind hantavirus particles or antigens from a biological sample, such as blood or plasma. The bound hantavirus particles or antigens are recovered from the column matrix by, for example, a change in pH.

Hantavirus Diagnostic Assays

As explained above, the immunogenic hantavirus antigens and antibodies to the antigens can be used in assays to identify hantavirus infection. Typically, the presence of hantavirus in a biological sample will be determined by the presence of antibodies to hantavirus in the sample, although in appropriate cases the presence of the viral proteins may be detected and used as an indicator of hantavirus in the sample. The reagents can be used for detecting hantavirus in blood samples, including without limitation, in whole blood, serum and plasma. The antigens and antibodies can be used to detect hantavirus infection in a subject, such as a human or rodent subject, as well as to detect hantavirus contamination in donated blood samples. Thus, aliquots from individual donated samples or pooled samples can be screened for the presence of hantavirus and those samples or pooled samples contaminated with hantavirus can be eliminated before they are combined. In this way, a blood supply substantially free of hantavirus contamination can be provided. By "substantially free of hantavirus" is meant that the presence of hantavirus is not detected using the assays described herein, preferably using the strip immunoblot assay described more fully below. Assays for use herein include Western blots; agglutination tests; enzyme-labeled and mediated immunoassays, such as ELISAs; biotin/avidin type assays; radioimmunoassays; immunoelectrophoresis; immunoprecipitation, strip immunoblot assays, and the like. The reactions generally include revealing labels such as fluorescent, chemiluminescent, radioactive, enzymatic labels or dye molecules, or other methods for detecting the formation of a complex between the antigen and the antibody or antibodies reacted therewith.

The aforementioned assays generally involve separation of unbound antibody or antigen in a liquid phase from a solid phase support to which antigen-antibody complexes are bound. Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidine fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like. In one aspect of the invention, the hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV, are used for capture or detection or both of anti-hantavirus antibodies in a sample. In another aspect of the invention, antibodies to the hantavirus antigens can be used for the capture or detection or both of hantavirus antigens in a sample. By "capture" of an analyte (i.e., anti-hantavirus antibodies or hantavirus antigens in a sample) is meant that the analyte can be separated from other components of the sample by virtue of the binding of the capture molecule. Typically, the capture molecule is associated with a solid support, either directly or indirectly. Typically, the detection molecule is associated with a detectable label, either directly or indirectly. Typically, a solid support is first reacted with a solid phase component (e.g., the hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV and/or anti-hantavirus antibodies) under suitable binding conditions such that the component is sufficiently immobilized to the support. Sometimes, immobilization to the support can be enhanced by first coupling to a protein with better binding properties. Suitable coupling proteins include, but are not limited to, macromolecules such as serum albumins including bovine serum albumin (BSA), keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, and other proteins well known to those skilled in the art. Other molecules that can be used to bind the antigen or antibody to the support include polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and the like. Such molecules and methods of coupling these molecules are well known to those of ordinary skill in the art. See, e.g., Brinkley, M.A. Bioconjugate Cheni. (1992) 3:2-13; Hashida et al., J. Appl. Biochem. (1984) 6:56-63; and Anjaneyulu and Staros, InternationalJ. of Peptide and Protein Res. (1987) 30:117-124.

After reacting the solid support with the solid phase component, any non-immobilized solid-phase components are removed from the support by washing, and the support-bound component is then contacted with a biological sample suspected of containing the ligand component (i.e., hantavirus antigens or antibodies) under suitable binding conditions. After washing to remove any non-bound ligand, a secondary binder moiety can be added under suitable binding conditions, wherein the secondary binder is capable of associating selectively with the bound ligand. The presence of the secondary binder can then be detected using techniques well known in the art.

More particularly, an ELISA method can be used, wherein the wells of a microtiter plate are coated with the hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV, and/or antibodies according to the present invention. A biological sample containing or suspected of containing either anti-hantavirus immunoglobulin molecules or hantavirus antigens is then added to the coated wells. After a period of incubation sufficient to allow antigen-antibody binding, the plate(s) can be washed to remove unbound moieties and a detectably labeled secondary binding molecule added. The secondary binding molecule is allowed to react with any captured sample, the plate washed and the presence of the secondary binding molecule detected using methods well known in the art.

In one particular format, an ELISA antigen sandwich format is used. In this case, the solid support is coated with the hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV. The sample is then contacted with the support under conditions that allow anti- hantavirus antibodies, if present, to bind one or more or the hantavirus antigens to form an antigen/antibody complex. Unbound reagents are removed and an enzymatically labeled antigen that reacts with the bound antigen/antibody complex, such as a labeled hantavirus N and/or Gl antigen, is added. An enzyme substrate is used to generate a signal.

In another format, the solid support is coated with species-specific anti- isotypic antibodies (e.g., anti-human IgM antibodies, anti-human IgG antibodies, anti- human IgA antibodies, etc). The support is then contacted with the sample under conditions that allow binding of antibodies present in the sample to the anti-isotypic antibodies. Unbound antibodies can be removed and the presence of bound anti- hantavirus antibodies is detected using labeled hantavirus antigens of the present invention. The label will typically be an enzyme label, e.g., a HRP, AP.

In another embodiment, the presence of bound hantavirus ligands from a biological sample can be readily detected using a secondary binder comprising an antibody directed against the antibody ligands. A number of anti-human immunoglobulin (Ig) molecules are known in the art which can be readily conjugated to a detectable enzyme label, such as horseradish peroxidase, alkaline phosphatase or urease, using methods known to those of skill in the art. An appropriate enzyme substrate is then used to generate a detectable signal. In other related embodiments, competitive-type ELISA techniques can be practiced using methods known to those skilled in the art. Other formats for detection of anti-hantavirus antibodies in a sample are known and the combination of hantavirus antigens of the present invention can be used with any known format that employs a hantavirus antigen. See, e.g., Lee et al., J. Infect. Dis. (1978) 137:298-308; Lee et al., J. Infect. Dis. (1982) 146:638-644; Lee et al., J. Infect. Dis. (1982) 146:645-651; Lundkvist et al., Clin. Diagnos. Lab. Immunol. (1995) 2:82-86; Chu et al., Virology (1994) 198:196-204; Elgh et al., J. Med. Virol (1995) 45:146-150; Hjelle et al., J Clin. Microbiol. (1997) 35:600-608; Bharadwaj et al., J. Infect. Dis. (2000) 182:43-48; Yee, et al., J. Wildl Dis. (2003) 39:271-277).

The hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV, can be used in an IgM capture ELISA as follows. Anti-human IgM antibodies (e.g., goat anti-human IgM antibodies) are attached to a solid support, the support is contacted with a sample to be tested for the presence of human IgM to hantavirus, under conditions that would allow the binding of the anti-hantavirus IgM, if present, to one or more of the anti- human IgM antibodies attached to the solid support, to form antibody/antibody complexes. The hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV are added under conditions that would allow binding to the anti-hantavirus IgM in the antibody/antibody complexes forming an antibody/antibody/antigen complex. Unbound antigens are removed and detectably labeled anti-hantavirus antibodies are added under conditions that would allow binding to the bound antigens. The presence of IgM to hantavirus in the sample is determined by the presence of detectably labeled anti-hantavirus antibodies to the bound anti-human IgM Ab/human anti- hantavirus IgM/ antigen complexes attached to the solid support. Alternatively, the hantavirus antigens themselves may be detectably labeled, this dispensing with the need for detectably labeled anti-hantavirus antibodies.

The hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV can also be used in an indirect IgG ELISA as follows. Antibodies specific for antigens are attached to a solid support, the support is contacted with the hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV under conditions that would allow binding to the anti-hantavirus antibodies bound to the support to form antibody/antigen complexes. Unbound antigens are removed and the support is contacted with a sample to be tested for the presence of human IgG to hantavirus under conditions that would allow binding of human anti-hantavirus IgG, if present, to the antigens in the antibody/antigen complexes. The presence of bound anti-hantavirus IgG can be detected using a detectably labeled anti-human IgG antibody.

While some of the foregoing assay formats are termed "ELISA" (Enzyme Linked ImmunoSorbant Assay) assays, it will be apparent to one of skill in the art that the use of a detectable label other than an "enzyme linked" binding moiety is possible and may be desirable in many situations. Other suitable detectable labels are described herein and are well known in the art.

Assays can also be conducted in solution, such that the hantavirus antigens or antibodies and ligands specific for these molecules form complexes under precipitating conditions. In one particular embodiment, the molecules can be attached to a solid phase particle (e.g., an agarose bead or the like) using coupling techniques known in the art, such as by direct chemical or indirect coupling. The coated particle is then contacted under suitable binding conditions with a biological sample suspected of containing hantavirus antibodies or antigens. Cross-linking between bound antibodies causes the formation of complex aggregates which can be precipitated and separated from the sample using washing and/or centrifugation. The reaction mixture can be analyzed to determine the presence or absence of complexes using any of a number of standard methods, such as those immunodiagnostic methods described above. In yet a further embodiment, an immunoaffinity matrix can be provided, wherein, for example, a polyclonal population of antibodies from a biological sample suspected of containing hantavirus antibodies is immobilized to a substrate. An initial affinity purification of the sample can be carried out using immobilized antigens. The resultant sample preparation will thus only contain anti-hantavirus moieties, avoiding potential nonspecific binding properties in the affinity support. A number of methods of immobilizing immunoglobulins (either intact or in specific fragments) at high yield and good retention of antigen binding activity are known in the art. Once the immunoglobulin molecules have been immobilized to provide an immunoaffinity matrix, labeled molecules are contacted with the bound antibodies under suitable binding conditions. After any non-specifically bound hantavirus antigen has been washed from the immunoaffinity support, the presence of bound antigen can be determined by assaying for label using methods known in the art.

In a particularly preferred embodiment of the invention, a strip immunoblot assay (SIA) is used to detect hantavirus antibodies in a biological sample using the hantavirus Gl and/or N antigens from at least the six hantavirus serotypes, HTNV, PUUV, SEOV, DOBV, SNV and ANDV, immobilized on the test strip. SIA techniques are well known in the art and combine traditional western and dot blotting techniques, e.g., the RJDBA^® (Chiron Corp., Emeryville, CA) SIA. In these assays, the hantavirus antigens are immobilized as individual, discrete portions, e.g., as bands or dots, on a membranous support. Thus, by "discretely immobilized" on a membrane support is meant that the antigens are present as separate components and not mixed, such that reactivity or lack thereof with each of the antigens present can be assessed. A biological sample suspected of containing antibodies to hantavirus is then reacted with the test membrane. Visualization of anti-hantavirus reactivity in the biological sample is accomplished using anti-human immunoglobulin enzyme-conjugates in conjunction with a colorimetric enzyme substrate. Internal controls, such as anti- human IgM antibody and anti-human IgG antibody, can also be present on the test membrane. The assay can be performed manually or used in an automated format.

Solid supports which can be used in the practice of the strip immunoblot assays include, but are not limited to, membrane supports derived from a number of primary polymers including cellulose, polyamide (nylon), polyacrylonitrile, polyvinylidene difluoride, polysulfone, polypropylene, polyester, polyethylene and composite resins consisting of combinations or derivatives of the above. Particularly preferred are supports derived from cellulose, such as nitrocellulose membranes, as well as nylon membranes. The substrate generally includes the desired membrane with an inert plastic backing as a support.

The amount of antigen applied to the membrane varies, depending on the antigen in question. Generally, the antigen will be applied to the strip in an amount of about 20-500 ng/strip, preferably 50-250 ng/strip, more preferably 75-150 ng/strip. One of skill in the art can readily determine the amount of antigen necessary to produce a useable result. Alternatively, two concentrations of the antigens can be present, such as a low concentration and a high concentration. Thus, for example, an SNV N antigen can be provided in a concentration as specified above, as well as in one or more additional bands, in a concentration of about, e.g., 25-200 ng, such as 50- 150 ng, e.g., 100 ng/strip. The high level control will be present in an amount sufficiently higher to give a highly positive result, such as at 200-500 ng, particularly 250-350 ng, e.g., 300 ng/strip. It is apparent that the concentration of antigen to be applied to the test strip will vary depending on the specific antigen used and can be readily determined by one of skill in the art.

The antiimmunoglobulin antibodies, such as anti-human IgM antibody, anti- human IgG antibody and/or anti-human IgA antibody, can be present in a single concentration, or in two concentrations, one low and one high. For example, anti-IgG antibody can be present in a concentration of about 50-250 ng/ml, more preferably about 75-200 ng/ml and most preferably about 100-185 ng/ml. A higher concentration of anti-IgG antibody can also be present along with the low concentration of anti-IgG, to provide another internal control, such as at a concentration of about 400-1200 ng/ml, more preferably about 450-1000 ng/ml and most preferably about 500-950 ng/ml.

After reacting the membrane support with the desired antigens and Ig molecules, any non-immobilized solid-phase components are removed from the membrane by washing, and the membrane-bound components are then contacted with a biological sample suspected of containing antibodies to hantavirus, under suitable binding conditions. After washing to remove any non-bound antibodies, a secondary binder moiety is added under suitable binding conditions, where the secondary binder is capable of associating selectively with bound antibodies. The presence of the secondary binder can then be detected using techniques well known in the art.

In a particularly preferred embodiment, the presence of bound anti-hantavirus antigen ligands from a biological sample can be readily detected using a secondary binder comprising an antibody directed against the antibody ligands. A number of anti-human immunoglobulin (Ig) molecules are known in the art such as commercially available goat anti-human Ig or rabbit anti-human Ig. Ig molecules for use herein will be of the IgG, IgA or IgM type. The Ig molecules can be readily conjugated to a detectable enzyme label, such as horseradish peroxidase, glucose oxidase, β-galactosidase, alkaline phosphatase and urease, among others, using methods known to those of skill in the art. An appropriate enzyme substrate is then used to generate a detectable signal.

Furthermore, a conjugate against human heavy-and light-chain antibodies can be used to render the SIA capable of detecting both IgG and IgM responses. This design may serve to increase sensitivity of detection of antibody responses in the early stages of infection. The above-described assay reagents, including hantavirus antigens and/or antibodies thereto, the solid supports with bound reagents, as well as other detection reagents, can be provided in kits, with suitable instructions and other necessary reagents, in order to conduct the assays as described above. The kit may also include control formulations (positive and/or negative), labeled reagents when the assay format requires same and signal generating reagents (e.g., enzyme substrate) if the label does not generate a signal directly. Instructions (e.g., written, tape, VCR, CD- ROM, etc.) for carrying out the assay usually will be included in the kit. The kit can also contain, depending on the particular assay used, other packaged reagents and materials (i.e. wash buffers and the like). Standard assays, such as those described above, can be conducted using these kits.

III. Experimental Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

Example 1

Cloning and Expression of Hantavirus Recombinant Gl Proteins The hantavirus Gl antigens shown in Table 2 were prepared as follows. Nucleotide fragments encoding recombinant Gl antigens including 80-83 amino acids of the Gl protein of HTNV, PUUV, SEOV, DOBV, SNV and ANDV were synthesized using a combination of oligonucleotides corresponding to the region of interest for each strain. The portion of the Gl protein sequence in the recombinant antigen is indicated in Table 2. These fragments were annealed, ligated and cloned into a subcloning vector and the correct nucleotide sequence was confirmed by DNA sequencing. The region of interest was excised by restriction endonuclease treatment and cloned along with the ADH2/GAPDH promoter fragment into pBS24.1. Plasmid pBS24.1 is a high copy number expression vector that has been extensively used to express a great variety of recombinant proteins (Pichuantes et al., J. Biol. Chem. (1990) 23:13890—13898; Pichuantes et al., "Expression of heterologous gene products in yeast." In: Cleland JL, Craik C, editors. Protein engineering: a guide to design and production (1996) New York, NY, Wiley-Liss, Inc., pp 129-161). It contains 2μ and inverted repeats (IR) sequences for autonomous replication, the α-factor terminator to ensure transcription termination, and the Ieu2-d and URA3, for selection. The β-lactamase gene for ampicillin resistance and the CoIEl origin of replication are also present in this vector for selection and autonomous replication in Escherichia coli.

For SOD fusion constructs, the region of interest was cloned into a genetically engineered pBS24.1 vector that already contained the ADH2/GAPDH promoter along with the human SOD gene. The nucleotide sequence and amino acid sequences of the human SOD used in the cloning of the hantavirus recombinant antigens is described in Hallewell et al., Bio/Technology (1987) 5:363-366. The resulting plasmids were transformed into S. cerevisiae strain AD3 and expression of the recombinant proteins was monitored by SDS-PAGE and immunoblot analysis. The various SOD/G1 fusions produced include the Gl sequences shown in Figures 7-12 fused to the C- terminus of the SOD sequence shown in Figure 19. The SOD/G1 fusions are represented by SEQ ID NOS:42-47.

The following protocol was followed to produce the SOD fusions. Although this discussion details the production of the SNV Gl /SOD fusion, the remaining fusions were produced in the same way. Since expression of extensive portions of the full-length Gl was hampered by instability and variable expression, a smaller (82- aa) portion of SNV Gl (residues 35-117 relative to the initiating methionine of isolate NM HlO) was used in a fusion with the human superoxide dismutase (SOD) sequence shown in Figure 19. The small Gl fragment was synthesized by PCR from pFCV-M- 1275 (Yamada et al., J. Virol (1995) 69:1939-1943) using primers that introduced an Ncol site on the 5'-end and a SaH site and two stop codons on the 3'-end. The 268 bp Ncoiy&z/I-digested fragment was used to replace the 347 bp insert of ρSOD/FirV2PR113 (Pichuantes et al., J. Biol. Chem. (1990) 265:13890-13898), creating the construct pSOD/Gl . A 603 bp Stul/Sall fragment of pSOD/Gl was ligated into the vector pSIl/PR179 (Pichuantes et al., Proteins Struct. Fund. Genet. (1989) 6:324-327) to provide the ADH2/GAPDH promoter. The 2093 bp BamHVSalI cassette of the resulting construct was then introduced into the yeast expression vector pBS24.1 to create the final expression construct pSOD/SΝV-Gl . The protein was expressed as a 23 kD SOD-Gl fusion in the protease-defϊcient (prbl 1122, pep 4-3) Saccharomyces cerevisiae strain AB 122 (Pichuantes et al., Protein Engineering Principles and Practice (1996) Chapter 5, pp. 129-161, Cleland and Craik, eds. Wiley-Liss, Inc., New York). The 82-aa portion of Gl expressed in this construct spans the immunodominant epitope and contains some additional flanking sequence. The sequence of the SNV Gl portion of the antigen is shown in Figure 1 IB. Table 2. Hantavirus Gl Anti ens Ex ressed in S. cerevisiae

*The amino acid sequences of the proteins produced also included a methionine (M) on the N-terminal end of the Gl sequences.

Example 2

Cloning and Expression of Hantavirus Recombinant N Proteins The hantavirus N antigens shown in Table 3 were prepared as follows. The genes for the Hantavirus nucleocapsid proteins of PUUV, SEOV, SNV and ANDV were amplified by PCR using DNA from hantavirus recombinant plasmids as templates. The portions of the hantavirus N protein sequence in the recombinant proteins is indicated in Table 3. The nucleocapsid genes of HTNV and DOBV were chemically synthesized. Cloning and expression was performed essentially as described above. The various N antigens produced are shown in Figures 13-18 and the SOD sequence that was present directly contiguous to the N-terminus of the N antigen/SOD fusions is shown in Figure 19. Table 3. Hantavirus N Anti ens Ex ressed in S. cerevisiae

Example 3

Purification of Hantavirus Recombinant Proteins The hantavirus proteins, recombinant produced as described above, were purified by lysing the transformed S. cerevisiae cells in lysis buffer (50 mM Tris, 0.15 M NaCl, 1 mM EDTA, pH 8) using a Dino-Mill apparatus. The lysate was washed several times with 1 -3 M urea in lysis buffer and protein was solubilized by increasing the pH to 11.5 and then subjected to gel filtration chromatography. The purification of recombinant ANDV G and DOBV G proteins also included ammonium sulfate precipitation and solubilization with PBS, 0.1% SDS, 1 mM EDTA.

Example 4

Polyclonal Antibody Production using the Hantavirus Recombinant Proteins

The purified recombinant SOD fused Gl antigens of HTNV, PUUV, SEOV, DOBV, SNV and ANDV and the recombinant non-fused N proteins of SEOV, DOBV, SNV and ANDV (see Tables 2 and 3 above) were used to produce rabbit polyclonal antibodies. Two rabbits were immunized and 50 ml of antiserum were produced. The polyclonal antibodies were then tested against the recombinant proteins using Western Blot analysis on a 4-20% Tris Glycine gel. The antibodies produced against each of the six Gl antigens were shown to be cross-reactive with the Gl antigens of the different subtypes. Similarly, the antibodies produced against each of the four N proteins were shown to be cross-reactive with the N antigens of the different subtypes.

Example 5

Strip Immunoblot Assay (SIA)

The recombinant Gl antigens and N antigens, with or without the SOD sequence, from the six serotypes, as described above are used in an SIA, such as the RIB A® test (Chiron Corp., Emeryville, CA). The membrane consists of nitrocellulose with an inert plastic backing as support. Six of the Gl antigens, one from each

HTNV, PUUV, SEOV, DOBV, SNV and ANDV, and six of the N antigens, one from each of HTNV, PUUV, SEOV, DOBV, SNV and ANDV, are applied in discrete bands to nitrocellulose strips at concentrations of 75-150 ng/strip. As internal controls, additional bands contain purified human IgG at a low level, Level I (50-150 ng/strip) and high level, Level II (250-350 ng/strip).

The assay procedure is performed according to the manufacturer's instructions. All steps are performed at room temperature. Each strip is numbered and then placed in a separate tube to which is added a 1 :50 dilution of human serum in a specimen diluent buffer (phosphate-buffered saline (PBS) with bovine protein stabilizers and detergents, 0.1% sodium azide and 0.05% gentamicin sulfate as preservatives). The tubes are rocked gently for 4 to 4.5 h, the solution removed by aspiration, and 1 ml of fresh diluent is added to each tube. The tubes are rocked for 30 minutes, the solution removed by aspiration and 1 ml of wash buffer made from wash buffer concentrate (50X) (phosphate-buffered detergent solution with 0.01% thimerosal as a preservative) is added to each tube. The contents of each tube are emptied into a single wash vessel and the strips are washed by swirling for 20 seconds. The wash buffer is decanted and 30 ml of fresh buffer added and the process repeated. Residual solution is removed by aspiration and 20 ml of conjugate solution (peroxidase-labeled goat anti-human IgG (heavy and light chains), with bovine protein stabilizers, containing 0.01% thimerosal as a preservative) is added. The vessel is rotated at 110 rpm for 9-11 minutes, the conjugate solution is decanted and the wash step is repeated three times. Residual solution is again removed by aspiration and 20 ml of substrate/developer (4-chloro-l-napthol in methanol/phosphate-buffered hydrogen peroxide) added, followed by rotation for 15-20 minutes at 110 rpm. The solution is decanted and the strips are washed twice in distilled water. Developed strips are placed face up on absorbent paper and allowed to dry for 30 minutes in the dark. A serum is considered reactive against a given antigen only if reactivity is greater than or equal to the level I IgG control band, which is defined to represent a 1+ reactivity. A reactivity equivalent to the level II IgG control band is considered to represent a reactivity of 3+. Reactivity intensity intermediate between the level I and level II IgG control bands is considered to be 2+, and reactivity stronger than the level II band is considered to be 4+.

Thus, novel methods for detecting hantavirus infection are disclosed. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as described herein.

Claims

Claims:

1. A method of detecting hantavirus antibodies in a biological sample, comprising: (a) contacting said biological sample with at least six hantavirus recombinant antigens, wherein the at least six hantavirus recombinant antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV) wherein at least one recombinant antigen from each of the serotypes is present, said contacting performed under conditions which allow hantavirus antibodies, when present in the biological sample, to bind to at least one of said Gl or N antigens to form an antibody/antigen complex; and

(b) detecting the presence or absence of said antibody/antigen complex, thereby detecting the presence or absence of hantavirus antibodies in said sample.

2. The method of claim 1, wherein said Gl antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:40.

3. The method of claim 2, wherein said Gl antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID

NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47.

4. The method of claim 1, wherein said N antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39.

5. The method of claim 4, wherein said N antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.

6. The method of claim 1, wherein said Gl antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:40 and said N antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39.

7. The method of claim 6, wherein said Gl antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47, and said N antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.

8. The method of any one of claims 1-7, wherein at least one Gl antigen is present from each of hantavirus serotypes HTNV, PUUV₅ SEOV, DOBV, SNV and ANDV, and at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV.

9. The method of any one of claims 1 , 4 or 5, wherein at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV.

10. An immunodiagnostic test kit for detecting hantavirus infection, said test kit comprising:

(a) at least six hantavirus recombinant antigens, wherein the at least six hantavirus recombinant antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV) wherein at least one antigen from each of the serotypes is present;

(b) and instructions for conducting the immunodiagnostic test.

11. The immunodiagnostic test kit of claim 10, wherein said Gl anfgen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:40.

12. The immunodiagnostic test kit of claim 11, wherein said Gl antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47.

13. The immunodiagnostic test kit of claim 10, wherein said N antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39.

14. The immunodiagnostic test kit of claim 13 , wherein said N antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.

15. The immunodiagnostic test kit of claim 10, wherein said Gl antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:40 and said N antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39.

16. The immunodiagnostic test kit of claim 15, wherein said Gl antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47, and said N antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:48, SEQ ID NO:49, SEQ ED NO:50, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.

17. The immunodiagnostic test kit of any one of claims 10-16, wherein at least one Gl antigen is present from each of hantavirus serotypes HTNV, PUUV,

SEOV, DOBV, SNV and ANDV, and at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV.

18. The immunodiagnostic test kit of any one of claims 10, 13 or 14, wherein at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV,

SEOV, DOBV, SNV and ANDV.

19. A method of detecting hantavirus antigens in a biological sample, comprising: (a) contacting said biological sample with at least six different antibodies, wherein each of said antibodies is specific for at least one of six hantavirus antigens, wherein the six hantavirus antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV), wherein at least one antibody specific for at least one antigen from each of the serotypes is present, wherein said contacting is done under conditions which allow hantavirus antigens, when present in the biological sample, to bind to said antibodies to form an antibody/antigen complex; and

(b) detecting the presence or absence of said antibody/antigen complex, thereby detecting the presence or absence of hantavirus antigens in said sample.

20. The method of claim 19, wherein said antibodies are monoclonal antibodies.

21. An immunodiagnostic test kit for detecting hantavirus infection, said test kit comprising:

(a) at least six different antibodies, wherein each of said antibodies is specific for at least one of six hantavirus antigens, wherein the six hantavirus antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV), wherein at least one antibody specific for at least one antigen from each of the serotypes is present; and (b) instructions for conducting the immunodiagnostic test.

22. The immunodiagnostic test kit of claim 21, wherein said antibodies are monoclonal antibodies.

23. A solid support comprising at least six hantavirus recombinant antigens, wherein the at least six hantavirus recombinant antigens comprise a combination of Gl and/or N antigens from hantavirus serotypes Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Dobrava (DOBV), Sin Nombre (SNV) and Andes (ANDV) wherein at least one antigen from each of the serotypes is present.

24. The solid support of claim 23, wherein said Gl antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:40.

25. The solid support of claim 24, wherein said Gl antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of

SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47.

26. The solid support of claim 23, wherein said N antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39.

27. The solid support of claim 26, wherein said N antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52 and SEQ ID NO:53.

28. The solid support of claim 23, wherein said Gl antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO: 40 and said N antigen(s) comprises an amino acid sequence corresponding to the amino acid sequence of SEQ ID NO:39.

29. The solid support of claim 28, wherein said Gl antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46 and SEQ ID NO:47, and said N antigen(s) is one or more antigens comprising an amino acid sequence selected from the group consisting of SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ED NO:52 and SEQ ID NO:53.

30. The solid support of any one of claims 23-29, wherein at least one Gl antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV, and at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV.

31. The solid support of any one of claims 23 , 26 or 27, at least one N antigen is present from each of hantavirus serotypes HTNV, PUUV, SEOV, DOBV, SNV and ANDV.

32. The solid support of any one of claims 23-31 , further comprising at least one anti-human immunoglobulin antibody, wherein the hantavirus antigens and the .anti-human immunoglobulin antibody are immobilized in discrete positions on the solid support.

33. The solid support of claim 32, wherein the at least one anti-human immunoglobulin antibody is selected from the group consisting of an anti-human IgM antibody, an anti-human IgG antibody and an anti-human IgA antibody.

34. The solid support of claim 33, wherein the solid support comprises an anti-human IgM antibody and an anti-human IgG antibody immobilized in discrete positions thereon.

35. The solid support of claim 34, wherein the solid support further comprises an anti-human IgA antibody immobilized in a discrete position on the solid support.

36. The solid support of any of claims 23-35, further comprising at least two internal controls, wherein one of the controls defines the lower detection limit for a positive result in an immunoassay using the solid support and the other control defines a highly positive result in an immunoassay using the solid support.

37. The solid support of any one of claims 23-36, wherein the solid support is a nitrocellulose strip.

38. An immunodiagnostic test kit for detecting hantavirus, said test kit comprising:

(a) a solid support according to any one of claims 23-37; and (b) instructions for conducting the immunodiagnostic test.

39. A method of detecting the presence of hantavirus antibodies in a biological sample, said method comprising:

(a) providing a biological sample; (b) providing a solid support according to any one of claims 23-37;

(c) contacting said biological sample with said solid support, under conditions which allow hantavirus antibodies, if present in the biological sample, to bind with at least one of the hantavirus antigens to form an antibody/antigen complex; and

(d) detecting the presence of the antibody/antigen complex, thereby detecting the presence of hantavirus antibodies in the biological sample.

40. The method of claim 39, further comprising:

(e) removing unbound hantavirus antibodies; (f) providing one or more moieties capable of associating with said antibody/antigen complex; and

(g) detecting the presence of said one or more moieties, thereby detecting the presence of hantavirus antibodies in the biological sample.

41. The method of claim 40, wherein said one or more moieties comprises a detectably labeled hantavirus antigen.

42. The method of claim 41, wherein the detectable label is an enzyme.

43. The method of any one of claims 1-9, 19, 20 and 39-42, wherein said biological sample is from a human blood sample.

44. A method of preparing a blood supply comprising whole blood, platelets, plasma or serum, substantially free of hantavirus comprising:

(a) screening aliquots of whole blood, platelets, plasma or serum from collected blood samples by the method of any one of claims 1-9, 19, 20 and 39-42;

(b) eliminating any samples in which a hantavirus antigen or a hantavirus antibody is detected; and (c) combining samples in which neither a hantavirus antigen or a hantavirus antibody is detected to provide a blood supply substantially free of hantavirus.

1/27

HTNV M Segment i tagtagtaga caccgcaaaa gaaagcagtc aatcagcaac atggggatat ggaagtggct

61 agtgatggcc agtttagtat ggcctgtttt gacactgaga aatgtctatg acatgaaaat

121 tgagtgcccc catacagtaa gttttgggga aaacagtgtg ataggttatg tagaattacc

181 ccccgtgcca ttggccgaca cagcacagat ggtgcctgag agttcttgta acatggataa

241 tcaccaatcg ttgaatacaa taacaaaata tacccaagta agttggagag gaaaggctga

301 tcagtcacag tctagtcaaa attcatttga gacagtgtcc actgaagttg acttgaaagg

361 aacatgtgtt ctaaaacaca aaatggtgga agaatcatac cgtagtagga aatcagtaac

421 ctgttacgac ctgtcttgca atagcactta ctgcaagcca acactataca tgattgtacc

481 aattcatgca tgcaatatga tgaaaagctg tttgattgca ttgggaccat acagagtaca

541 ggtggtttat gagagaagtt actgtatgac aggagtcctg attgaaggga aatgctttgt

601 cccagatcaa agtgtggtca gtattatcaa gcatgggatc tttgatattg caagtgttca

661 tattgtatgt ttctttgttg cagttaaagg gaatacttat aaaatttttg aacaggttaa

721 gaaatccttt gaatcaacat gcaatgatac agagaataaa gtgcaaggat attatatttg

781 tattgtaggg ggaaactctg caccaatata tgttccaaca cttgatgatt tcagatccat

841 ggaagcattt acaggaatct tcagatcacc acatggggaa gatcatgatc tggctggaga

901 agaaattgca tcttattcta tagtcggacc tgccaatgca aaagttcctc atagtgctag

961 ctcagataca ttgagcttga ttgcctattc aggtatacca tcttattctt cccttagcat

1021 cctaacaagt tcaacagaag ctaagcatgt attcagccct gggttgttcc caaaacttaa

1081 tcacacaaat tgtgataaaa gtgccatacc actcatatgg actgggatga ttgatttacc

1141 tggatactac gaagctgtcc acccttgtac agttttttgc gtattatcag gtcctggggc

1201 atcatgtgaa gccttttctg aaggcgggat tttcaacata acctctccca tgtgcttagt

1261 gtcaaaacaa aatcgattcc ggttaacaga acagcaagtg aattttgtgt gtcagcgagt

1321 ggacatggac attgttgtgt actgcaacgg gcagaggaaa gtaatattaa caaaaactct

1381 agttattgga cagtgtatat atactataac aagcttattc tcattactac ctggagtagc

1441 acattctatt gctgttgaat tgtgtgtacc tgggttccat ggttgggcca cagctgctct

1501 gcttgttaca ttctgtttcg gatgggttct tataccagca attacattta tcatactaac

1561 agtcctaaag ttcattgcta atatttttca cacaagtaat caagagaata ggctaaaatc

1621 agtacttaga aagataaagg aagagtttga aaaaacaaaa ggctcaatgg tatgtgatgt

1681 ctgcaagtat gagtgtgaaa cctataaaga attaaaggca cacggggtat catgccccca

1741 atctcaatgt ccttactgtt ttactcattg tgaacccaca gaagcagcat tccaagctca

1801 ttacaaggta tgccaagtta ctcacagatt cagggatgat ctaaagaaaa ctgttactcc

1861 tcaaaatttt acaccaggat gttaccggac actaaattta tttagataca aaagcaggtg

1921 ctacatcttt acaatgtgga tatttcttct tgtcttagaa tccatactgt gggctgcaag

1981 tgcatcagag acaccattaa ctcctgtctg gaatgacaat gcccatgggg taggttctgt

2041 tcctatgcat acagatttag agcttgattt ctctttaaca tccagttcca agtatacata

2101 ccgtaggaag ttaacaaacc cacttgagga agcacaatcc attgacctac atattgaaat

2161 agaagaacag acaattggtg ttgatgtgca tgctctagga cactggtttg atggtcgtct

2221 taaccttaaa acatcctttc actgttatgg tgcttgtaca aagtatgaat acccttggca

2281 tactgcaaag tgccattatg aaagagatta ccaatatgag acgagctggg gttgtaatcc

2341 atcagattgt cctggggtgg gcacaggctg tacagcatgt ggtttatacc tagatcaact

2401 gaaaccagtt ggtagtgctt ataaaattat cacaataagg tacagcagga gagtctgtgt

2461 tcagtttggg gaggaaaacc tttgtaagat aatagacatg aatgattgtt ttgtatctag

2521 gcatgttaag gtctgcataa ttggtacagt atctaaattc tctcagggtg ataccttatt

2581 gttttttgga ccgcttgaag gtggtggtct aatatttaaa cactggtgta catccacatg

2641 tcaatttggt gacccaggag atatcatgag tccaagagac aaaggttttt tatgccctga

2701 gtttccaggt agtttcagga agaaatgcaa ctttgctact acccctattt gtgagtatga

2761 tggaaatatg gtctcaggtt acaagaaagt gatggcgaca attgattcct tccaatcttt

2821 taatacaagc actatgcact tcactgatga aaggatagag tggaaagacc ctgatggaat

2881 gctaagggac catataaaca ttttagtaac gaaggacatt gactttgata accttggtga

2941 aaatccttgc aaaattggcc tacaaacatc ttctattgag ggggcctggg gttctggtgt

3001 ggggttcaca ttaacatgtc tggtatcact aacagaatgt cctacctttt tgacctcaat

3061 aaaggcttgt gataaggcta tctgttatgg tgcagagagt gtaacattga caagaggaca

3121 aaatacagtc aaggtatcag ggaaaggtgg ccatagtggt tcaacattta ggtgttgcca

3181 tggggaggac tgttcacaaa ttggactcca tgctgctgca cctcaccttg acaaggtaaa

3241 tgggatttct gagatagaaa atagtaaagt atatgatgat ggggcaccgc aatgtgggat

3301 aaaatgttgg tttgttaaat caggggaatg gatttcaggg atattcagtg gtaattggat

3361 tgtactcatt gtcctctgtg tatttctatt gttctccttg gttttactaa gcattctctg

3421 tcccgtaagg aagσataaaa aatcatagct aaattctgtg actatcctgt tcttatgtat

3481 agctttaaca tatatactaa tttttatatt ccagtatact ctatctaaca cactaaaaaa

3541 aatagtagct ttctaaccac aaaacttaga ttcttcttct gtatgatgtc ttaacatctt

3601 gcggtgtcta ctacta

FIGURE IA (SEQ ID NO:1) 2/27

i MGIWKWLVMA SLVWPVLTLR NVYDMKIECP HTVSFGENSV IGYVELPPVP LADTAQMVPE

61 SSCNMDNHQS LNTITKYTQV SWRGKADQSQ SSQNSFETVS TEVDLKGTCV LKHKMVEESY 121 RSRKSVTCYD LSCNSTYCKP TLYMIVPIHA CNMMKSCLIA LGPYRVQWY ERSYCMTGVL 181 IEGKCFVPDQ SWSIIKHGI FDIASVHIVC FFVAVKGNTY KIFEQVKKSF ESTCNDTENK 241 VQGYYICIVG GNSAPIYVPT LDDFRSMEAF TGIFRSPHGE DHDLAGEEIA SYSIVGPANA 301 KVPHSASSDT LSLIAYSGIP SYSSLSILTS STEAKHVFSP GLFPKLNHTN CDKSAIPLIW 361 TGMIDLPGYY EAVHPCTVFC VLSGPGASCE AFSEGGIFNI TSPMCLVSKQ NRFRLTEQQV 421 NPVCQRVDMD IWYCNGQRK VILTKTLVIG QCIYTITSLF SLLPGVAHSI AVELCVPGFH 481 GWATAALLVT FCFGWVLIPA ITFIILTVLK FIANIFHTSN QENRLKSVLR KIKEEFEKTK 541 GSMVCDVCKY ECETYKELKA HGVSCPQSQC PYCFTHCEPT EAAFQAHYKV CQVTHRFRDD 601 LKKTVTPQNF TPGCYRTLNL FRYKSRCYIF TMWIFLLVLE SILWAASASE TPLTPVWNDN 661 AHGVGSVPMH TDLELDFSLT SSSKYTYRRK LTNPLEEAQS IDLHIEIEEQ TIGVDVHALG 721 HWFDGRLNLK TSFHCYGACT KYEYPWHTAK CHYERDYQYE TSWGCNPSDC PGVGTGCTAC 781 GLYLDQLKPV GSAYKIITIR YSRRVCVQFG EENLCKIIDM NDCFVSRHVK VCIIGTVSKF 841 SQGDTLLFFG PLEGGGLIFK HWCTSTCQFG DPGDIMSPRD KGFLCPEFPG SFRKKCNFAT 901 TPICEYDGNM VSGYKKVMAT IDSFQSFNTS TMHFTDERIE WKDPDGMLRD HINILVTKDI 961 DFDNLGENPC KIGLQTSSIE GAWGSGVGFT LTCLVSLTEC PTFLTSIKAC DKAICYGAES 1021 VTLTRGQNTV KVSGKGGHSG STFRCCHGED CSQIGLHAAA PHLDKVNGIS EIENSKVYDD 1081 GAPQCGIKCW FVKSGEWISG IFSGNWIVLI VLCVFLLFSL VLLSILCPVR KHKKS

FIGURE IB (SEQ ID NO : 2)

3/27

PUUV M SEGMENT

l tagtagtaga ctccgcaaga agaagcaaac acagatcaat atgggagaac ttagtccagt 61 ttgtctgtat ctgcttctcc agggtctatt actatgtaat acaggggctg ccagaaacct

121 taatgagctt aaaatggaat gtccacatac tattagatta gggcagggtc ttgttgtggg

181 ttcagtagaa ttgccatctc ttccaataca gcaggtcgag acactaaagc tggagagttc

241 ttgtaatttt gatctacata ccagtacagc aggacaacaa tcattcacaa aatggacatg

301 ggaaattaaa ggtgatcttg cagagaacac acaggcatca tcaacaagtt ttcaaacaaa

361 aagcagtgaa gtgaatttga gaggattatg tttgatccct actttagtgg ttgaaacagc

421 agcaagaatg cgaaaaacaa tagcatgtta tgacctgtca tgcaatcaaa cagtgtgtca

481 gcctactgtc tatttaatgg gacctatcca gacttgtata acaactaaaa gttgtctctt

541 gagtttaggt gatcaaagga ttcaagtaaa ttatgaaaaa acatactgtg tttctgggga

601 ccttgttgaa ggtatctgtt ttaatccaat acatacaatg gcactctctc aacctagtca

661 tacatatgat ataatgaoca tgatggttcg ctgtttcttg gtaataaaga aagtgacttc

721 tggtgacagt atgaagattg aaaagaactt tgagactctt gttcaaaaaa atggctgcac

781 agctaataac ttccaagggt attatatctg tcttataggg agtagttcag agcccttata

841 tgttccagca ttagatgatt atcgttcagc tgaagttctt tcaaggatgg catttgcacc

901 acatggtgaa gatcatgata ttgagaaaaa tgcagtgagt gcaatgcgta ttgctggaaa

961 ggtgacagga aaggtgccat caacagaato atcagataca gtacagggga ttgcattttc

1021 aggtagtcct ctttatacat ctactggtgt cttgacatca aaagatgatc ctgtctacat

1081 ttgggctcct ggaatcataa tggaaggaaa ccattctatt tgtgaaaaga agaccttacc

1141 ccttacatgg actggtttta tttcattgcc tggagagatt gaaaaaacaa cacaatgtac

1201 agtattttgt acattggctg gaccaggtgc agattgtgaa gcttactctg aaacaggcat

1261 cttcaacata agttcaccta cttgcttaat aaatcgtgtc cagagattcc gtggttcaga

1321 acagcaaata aagtttgtgt gccagagagt ggacatggat atcactgttt actgtaatgg

1381 gatgaagaaa gtcattctca ccaagaccct agttattgga caatgcattt atacttttac

1441 tagtattttc tctctaatcc ctggtgttgc acattccctt gctgttgaat tatgtgtacc

1501 tggtcttcat ggttgggcaa ctatgctatt attactaaca ttttgttttg gctgggtctt

1561 aataccaact ataacaatga tcctgctaaa gatattgatt gcattcgcat acttatgttc

1621 taaatataac acagattcga aattcaggat cttgattgag aaagtgaaaa gagagtacca

1681 gaaaacaatg ggttcaatgg tttgtgaagt gtgtcagtat gaatgtgaga ctgcaaaaga

1741 actggagtca catagaaaga gttgttccat tggttcatgc ccttattgtc tcaatccatc

1801 tgaggcaaca acatctgccc ttcaggctca ttttaaagtg tgtaagctca gatcacggtt

1861 tcaggagaat ttaagaaagt cattaacggt atatgagcct atgcaagggt gctaccggac

1921 tttatccctc tttagatata ggagtcggtt ctttgtgggt ctagtctggt gcgtgttatt

1981 ggttcatcac ttaattgtat gggctgccag tgctgaaaca caaaatttaa atgcaggttg

2041 gacagacaca gcacatggat ctagaattat acctatgaaa actgatctgg aattagactt

2101 ctctcttcag tcatcagcaa gctatacata taggagacag ctacaaaacc cagcaaacga

2161 acaagagaaa atcccatttc atctgcagtt aagcaaacaa gtgattcatg cagagatcca

2221 gcatttaggt cattggatgg atgctacatt taatcttaaa actgcatttc actgctatgg

2281 ctcatgtgag aagtatgctt atccttggca gacagcaggt tgtttcatag aaaaagatta

2341 tgaatatgag actggttggg gttgtaatcc acctgattgc ccaggggtag ggacaggctg

2401 tactgcttgt ggggtatacc ttgataaatt aaaatcagtt ggaaaggttt tcaaaattgt

2461 gtccttaaga tacacaagga aagtatgcat tcagttgggc acagaacaaa catgtaagac

2521 tgttgatagt aatgactgtc tcattaccac ttcagttaaa gtgtgcttga tagggaccat

2581 atcaaaattc caaccatctg acactttgct atttctaggt ccactacagc agggtggtct

2641 gatatttaaa caatggtgca ctacaacatg ccagtttggc gatcccgggg acataatgag

2701 cacacctaca ggcatgaagt gcccagaatt aaatggttct tttagaaaga aatgtgcatt

2761 tgcaacaact ccagtttgcc agtttgatgg aaatacaatt tcaggctata agaggatgat

2821 tgccacaaag gattcatttc aatctttcaa tgtgacagaa ccccatattt ctacaagtgc

2881 acttgaatgg attgatcctg acagctcact tagggaccat attaatgtaa ttgtgagtcg

2941 tgatctatcc ttccaagacc taagtgaaac accatgtcaa attgatttag caacagcctc

3001 tatagatgga gcatggggtt caggagttgg ttttaatctg gtttgtactg ttagtttaac

3061 agaatgttct gcatttctga catcaatcaa ggcctgtgat gctgcaatgt gttatgggtc

3121 caccaσagcc aatctagttc gagggcaaaa taccattcat atcgtcggta agggtgggca

3181 ttctggttca aaatttatgt gttgtcatga cacaaaatgt tctagcacog gtctagttgc

3241 agctgcacca cacttagatc gtgtgacacc atacaatcag gctgatagtg acaaaatctt

3301 tgatgatggg gcaccagaat gtggtatgtc atgttggttt aaaaaatcag gtgaatggat

3361 tcttggggtt ttgaacggga attggatggt tgttgctgta ctggtagtat tactgatctt

3421 gtccatactc ttattcacat tatgttgtcc tcgtagacct agttacagga aagaacataa

3481 gccctaagtt ttgcttacta acataattat tgtattctgt ttattgacac aattaccata

3541 tgattaactg tattccccca tcttatatct tatataatat tctttattta atcactatat

3601 agaaaaaaaa ctagcacttt actaattaaa ttaccccata ccgattatgc ctggactttt

3661 gttcttgcgg agtctactac ta

FIGURE 2A (SEQ ID NO: 3) 4/27

i MGELSPVCLY LLLQGLLLCN TGAARNLNEL KMECPHTIRL GQGLWGSVE LPSLPIQQVE

61 TLKLESSCNF DLHTSTAGQQ SFTKWTWEIK GDLAENTQAS STSFQTKSSE VNLRGLCLIP 121 TLWETAARM RKTIACYDLS CNQTVCQPTV YLMGPIQTCI TTKSCLLSLG DQRIQVNYEK 181 TYCVSGDLVE GICFNPIHTM ALSQPSHTYD IMTMMVRCFL VIKKVTSGDS MKIEKNFETL 241 VQKNGCTANN FQGYYICLIG SSSEPLYVPA LDDYRSAEVL SRMAFAPHGE DHDIEKNAVS 301 AMRIAGKVTG KVPSTESSDT VQGIAFSGSP LYTSTGVLTS KDDPVYIWAP GIIMEGNHSI 361 CEKKTLPLTW TGFISLPGEI EKTTQCTVFC TLAGPGADCE AYSETGIFNI SSPTCLINRV 421 QRFRGSEQQI KFVCQRVDMD ITVYCNGMKK VILTKTLVIG QCIYTFTSIF SLIPGVAHSL 481 AVELCVPGLH GWATMLLLLT FCFGWVLIPT ITMILLKILI AFAYLCSKYN TDSKFRILIE 541 KVKREYQKTM GSMVCEVCQY ECETAKELES HRKSCSIGSC PYCLNPSEAT TSALQAHFKV 601 CKLRSRFQEN LRKSLTVYEP MQGCYRTLSL FRYRSRFFVG LVWCVLLVHH LIVWAASAET 661 QNLNAGWTDT AHGSRIIPMK TDLELDFSLQ SSASYTYRRQ LQNPANEQEK IPFHLQLSKQ 721 VIHAEIQHLG HWMDATFNLK TAFHCYGSCE KYAYPWQTAG CFIEKDYEYE TGWGCNPPDC 781 PGVGTGCTAC GVYLDKLKSV GKVFKIVSLR YTRKVCIQLG TEQTCKTVDS NDCLITTSVK 841 VCLIGTISKF QPSDTLLFLG PLQQGGLIFK QWCTTTCQFG DPGDIMSTPT GMKCPELNGS 901 FRKKCAFATT PVCQFDGNTI SGYKRMIATK DSFQSFNVTE PHISTSALEW IDPDSSLRDH 961 INVIVSRDLS FQDLSETPCQ IDLATASIDG AWGSGVGFNL VCTVSLTECS AFLTSIKACD 1021 AAMCYGSTTA NLVRGQNTIH IVGKGGHSGS KFMCCHDTKC SSTGLVAAAP HLDRVTPYNQ 1081 ADSDKIFDDG APECGMSCWF KKSGEWILGV LNGNWMWAV LWLLILSIL LFTLCCPRRP 1141 SYRKEHKP

FIGURE 2B (SEQ ID NO: 4)

5/27

SEOV M SEGMENT i tagtagtaga ctccgcaaga aacagcagtt aaataacagc aggatcatgt ggagtttgct

61 attactggcc gctttagttg gccaaggctt tgcattaaaa aatgtgtttg acatgagaat

121 tcagtgcccc cactcagtca aatttgggga aacaagtgtg tcaggctaca cagaactgcc

181 cccactctca ttacaggagg cagaacagct ggtgccagag agctcatgca acatggacaa

241 ccaccaatca ctctcaacaa taaataaatt aaccaaggtc atatggcgga aaaaggcaaa

301 tcaggaatca gcaaaccaga attcatttga acttatggag agtgaagtca gctttaaagg

361 gttgtgtatg ttaaagcata gaatggttga agaatcctac agaaatagga gatcagtaat

421 ctgttatgat ctagcctgta atagtacatt ctgtaagcca actgtctaca tgattgttcc

481 tatacatgca tgcaacatga tgaaaagctg tttgattggt cttggtcctt acagagtcca

541 ggtcgtttat gaaaggacat actgcactac gggtatattg acagaaggaa aatgctttgt

601 tcctgacaag gctgtcgtca gtgcattgaa gagaggcatg tacgccatag caagcataga

661 gacaatctgc ttttttattc atcagaaagg gaatacatat aagatagtga ctgccatcac

721 atcggcaatg ggctccaaat gtaataatac agatactaaa gttcaagggt attatatctg

781 tattattggt gggaactctg cccccgtata tgcccctgct ggtgaagact ttagggcaat

841 ggaggttttt tccgggatta ttacatcacc gcatggagaa gaccatgatc tccctggcga

901 agaaattgca acataccaga tttcagggca gatagaggca aaaatccctc atacagtgag

961 ctccaagaac ttaaaattga ctgcttttgc aggtattoca tcatactcat caaccagtat

1021 attgactgct tcagaagatg gtcgtttcat atttagtcct ggtctatttc ctaacctaaa

1081 tcagtcagtc tgtgacaaca atgcactccc tttaatctgg aggggcctaa ttgatttaac

1141 aggatactat gaggcagtcc acccttgcaa tgtattctgt gtcttatcag gaccaggtgc

1201 ttcatgtgaa gccttttcag aaggaggtat tttcaatatt acttccccaa tgtgtcttgt

1261 gtccaagcaa aataggttta gagcagctga gcagcagatc agctttgttt gccaaagggt

1321 tgatatggat attatagtgt actgtaatgg tcagaaaaag acaatcctaa caaaaacatt

1381 agttataggc caatgcattt atactattac aagtctcttt tcactgttac caggggttgc

1441 ccattctatt gctattgagt tgtgtgttcc aggatttcat ggctgggcca cagctgcact

1501 tttgatcaca ttctgctttg gctgggtatt gattcctgca tgtacattag ctattctttt

1561 agttcttaag ttttttgcaa atatcctcca cacaagcaat caagagaacc gattcaaagc

1621 cattctacgg aaaataaagg aggagtttga aaaaacaaag ggttccatgg tttgtgagat

1681 ctgtaagtac gagtgtgaaa cattaaagga attgaaggca cataatctat catgtgttca

1741 aggggaatgc ccatattgot ttacccactg tgaaccgaca gaaactgcaa ttcaggcaca

1801 ttacaaagtt tgtcaagcca cccaccgatt cagagaagat ttaaaaaaga ctgtgactcc

1861 tcaaaatatt gggcctggtt gttaccgaac attaaatctt tttaggtata aaagtaggtg

1921 ttatattctg acaatgtgga ctcttcttct cattattgaa tccattctct gggcagcaag

1981 tgcagcagaa atccccottg tccctctctg gacagataat gctcatggtg ttgggagtgt

2041 tcctatgcat acagaccttg aattagactt ttctttgcca tctagttcta ggtacacata

2101 taaaagacat ctcacaaacc cagttaatga ccaacagagt gtctcattgc acatagaaat

2161 tgaaagtcaa ggcattggtg ctgatgtcca tcatcttgga cattggtatg atgcaagatt

2221 gaatttaaaa acctcatttc attgttatgg tgcctgcaca aaatatcaat atccatggca

2281 cactgcaaaa tgccattttg agaaagatta tgagtatgaa aatagctggg catgcaaccc

2341 cccagattgc ccaggggttg gtacaggttg tactgcttgt gggttatatc tcgatcaatt

2401 gaagccggta ggaacagcct ttaaaattat aagtgtaaga tacagtagaa aagtgtgcgt

2461 gcagtttggt gaagagtaoc tttgtaaaac aattgatatg aacgattgct ttgtgactag

2521 gcatgccaaa atatgtataa ttgggactgt atctaagttt tctcaaggtg acactctact

2581 atttctgggg cccatggaag gaggtggtat aatctttaaa cactggtgca cgtctacctg

2641 tcactttgga gaccctggtg atgtcatggg tccaaaggat aaaccattta tttgccctga

2701 attcccaggg caattcagga aaaaatgtaa ctttgccaca actccagttt gtgaatatga

2761 tgggaatatt atctcaggct ataagaaagt tcttgcaaca attgattctt tccaatcatt

2821 taacacaagc aatatacact tcactgatga gagaattgaa tggagagacc ctgatggtat

2881 gcttcgggat catattaata tcgttatttc taaagatatt gattttgaaa atttggctga

2941 gaatccttgt aaagtagggc tccaggcagc aaacatagaa ggtgoctggg gttcaggtgt

3001 cgggtttaca ctcacatgcc aggtgtctct cacagaatgc ccaacatttc tcacgtcaat

3061 aagggcctgt gacatggcaa tttgttatgg tgcagaaagt gtgacactct cacgaggaca

3121 aaatactgtc aaaattaccg ggaaaggtgg ccatagtggt tcctcattta agtgctgtca

3181 tgggaaagaa tgttcattaa ctggcctcca agccagtgca ccacatttag ataaggtaaa

3241 tggaatctct gagttagaaa atgagaaagt ttatgatgat ggtgcacctg aatgtggcat

3301 tacttgttgg tttaaaaaat caggtgaatg ggttatgggt ataatcaatg ggaactgggt

3361 tgtcctaatt gtcttgtgtg tcctgctgct cttttctctt atcctgttga gcatcctgtg

3421 tcctgttaga aagcataaaa aatcataaat cctgcttatt aatcttcata gcatgtatcg

3481 agttttaaac actttaccat taaaaactta acctggctct aatatctgat aactaacttt

3541 catttttatt tttatatgga ttaattacta aaaaaaatac tctcttctat ctcccaatct

3601 tttattgatt caccggggtg ttgtcttgac atcttgcgga gtσtactact a

FIGURE 3A (SEQ ID NO: 5) 6/27

1 MWΞLLLLAAL VGQGFALKNV FDMRIQCPHS VKFGETSVSG YTELPPLSLQ EAEQLVPESS

6i CNMDNHQSLS TINKLTKVIW RKKΆNQESAN QNSFELMESE VSFKGLCMLK HRMVEESYRN

121 RRSVICYDLA CNSTFCKPTV YMIVPIHACN MMKSCLIGLG PYRVQWYER TYCTTGILTE 181 GKCFVPDKAV VSALKRGMYA IASIETICFF IHQKGNTYKI VTAITSAMGS KCNNTDTKVQ 241 GYYICIIGGN SAPVYAPAGE DFRAMEVFSG IITSPHGEDH DLPGEEIATY QISGQIEAKI 301 PHTVSSKNLK LTAFAGIPSY SSTSILTASE DGRFIFSPGL FPNLNQSVCD NNALPLIWRG 361 LIDLTGYYEA VHPCNVFCVL SGPGASCEAF SEGGIFNITS PMCLVSKQNR FRAAEQQISF 421 VCQRVDMDII VYCNGQKKTI LTKTLVIGQC IYTITSLFSL LPGVAHSIAI ELCVPGFHGW 481 ATAALLITFC FGWVLIPACT LAILLVLKFF ANILHTSNQE NRFKAILRKI KEEFEKTKGS 541 MVCEICKYEC ETLKELKAHN LSCVQGECPY CFTHCEPTET AIQAHYKVCQ ATHRFREDLK 601 KTVTPQNIGP GCYRTLNLFR YKSRCYILTM WTLLLIIESI LWAASAAEIP LVPLWTDNAH 661 GVGSVPMHTD LELDFSLPSS SRYTYKRHLT NPVNDQQSVS LHIEIESQGI GADVHHLGHW 721 YDARLNLKTS FHCYGACTKY QYPWHTAKCH FEKDYEYKNS WACNPPDCPG VGTGCTACGL 781 YLDQLKPVGT AFKIISVRYS RKVCVQFGEE YLCKTIDMND CFVTRHAKIC IIGTVSKFSQ 841 GDTLLFLGPM EGGGIIFKHW CTSTCHFGDP GDVMGPKDKP FICPEFPGQF RKKCNFATTP 901 VCEYDGNIIS GYKKVLATID SFQSFNTSNI HFTDERIEWR DPDGMLRDHI NIVISKDIDF 961 ENLAENPCKV GLQAANIEGA WGSGVGFTLT CQVSLTECPT FLTSIRACDM AICYGAESVT 1021 LSRGQNTVKI TGKGGHSGSS FKCCHGKECS LTGLQASAPH LDKVNGISEL ENEKVYDDGA 1081 PECGITCWFK KSGEWVMGII NGNWWLIVL CVLLLFSLIL LSILCPVRKH KKS

FIGURE 3 B (SEQ ID NO : 6 )

7/27

DOBV M SEGMENT

1 tagtagtaga ctccgcaaga aacagcagtt aaataacagc atgatcatgt ggggtctact

61 attgacaatg attttgatcg attttggggc atccttaagg aatgtttatg acatgaagat

121 agaatgccca cattoaatca actttgggga gagcagtgta acaggtaagg tggaattacc

181 accccttctg ctoacagatg cagaggcctt ggtcccggag agttcttgta acatggacaa

241 ccatcagtct atgtcaatta tacaaaaagt gacaaaagtg agttggagaa aaaaggcaga

301 caaagcccaa gctgccaagg actcatttga gacaacatca agcgaggtta atctgaaggg

361 gacatgcaca ttgagtcata ggatggttga agaatcctac aggaatagga gatcagtgat

421 atgctatgac ttgtcttgca attcaacaca ttgtaagcca acgatgcata tgattgtgcc

481 tgtgcactca tgcaacatga tgaaaagctg tctggttggg cttgggcctt atcgaatcca

541 agttgtctat gaaagaacct actgtacaac tggtatacta acagaaggga agtgttttgt

601 gccagaccag agtattgtca gtgtcatcaa gaatggggtt tttgacattg caagtgtgag

661 cattgtctgt ttttttatca gagttaaagg aactaactac aagataatgg cgagtattaa

721 aacagcaact gcaaataact gtaatgacac tgacaataag gttcaaggat attacctttg

781 tattgttggg ggaaattctt ctcctgtgta tgoaccttca accactgatt ttagatctat

841 ggaagcactt gctagccttt taagagctcc tcatggtgag gaccatgatt tatctggaga

901 agaggttgca acttattcaa ttgccgggca aattgaaggc aaaatcccac atactgcaaa

961 tgcagcaaac atgctattta ctgcattctc aggaattcct agttactctt cattgagtgt

1021 ttttattgga agtcaagatg ggcctattat ttatagccca ggattgtttc ccaagttgaa

1081 ccaatcttca tgtgataagg tcgcactacc attgatatgg gaagggtaca tagatctacc

1141 tggctattat gaaacagttc acccgtgtaa tgtcttttgt gtgctatctg gcccaggagc

1201 atcatgtgag gcattctcag aaggtggtat tttcaatatt acatccccta catgccttgt

1261 gtcaaagcaa aatcggttca gggcagctga gcagcaagtc aatttcgtat gccagcgagt

1321 cgaccaagac attattatct actgtaatgg acaaaagaag acaattttga ccaagacatt

1381 agtgattggg cagtgtattt attcagtgac tagtttgttt tcaataatgc ctggggtagc

1441 acattcaatt gcaatcgaat tatgtgtacc agggttccat ggctgggcaa ctgctgctct

1501 tctcaccaca ttctgctttg gctggatact gatcccttcc atcacattgg ctgtattggt

1561 tgtcttaaag ttttttgcag caatcttaca taatagctct caagaaaacc gttttaaaat

1621 tatcctaagg aagattaaag aagaatttga aaagactaag ggctcaatgg tttgtgaagt

1681 gtgcaagtat gagtgtgaaa cagggaagga gcttaaagcc cataatttgt cttgccctca

1741 gtcacagtgt ccttattgct ttacacattg tgagcctaca gaatctgcct tccaggcaca

1801 ttataaagtg tgccaggcaa cacacaggtt tagagatgat ttgaagaaaa caataacacc

1861 tcaatctaca agcccgggtt gttaccggac attaaatctc tttaggtata aaagtaggtg

1921 ttacattttt acagtgtggg tcaccctgct aatcattgaa tcaatcatgt gggcagctag

1981 cgcatcagaa aatgttttgg agccaagctg gaatgacaac gcacatggtg ttggtgttgt

2041 cccaatgcat actgatctgg aactagattt ttctcttccg tcaagttcta agtacacata

2101 taaaagaaaa ctgacaagtc cattaaatca agaacaatca gtagatcttc acatagagat

2161 agagagtcaa gggatttcta caagtgttca tgcattaggt cattggtttg atgggagact

2221 taatttaaag acatcttttc attgttatgg tgcatgtact aagtatgaat atccttggca

2281 tacagcaaaa tgccactttg aaagggattt cgagtatgag aacagctggg gctgtaatcc

2341 tgctgattgc cctgggattg gtacgggctg tactgcatgc ggactataca ttgaccaact

2401 taaacctgta ggcagtgcat acaagctaat cacagtccgt tacagccgta aagtatgtgt

2461 tcagtttggt gaagaaaacc tatgtaagac aattgacatg aatgattgct ttgttacaag

2521 acatgtcaaa gtatgcatta taggtacagt ttcaaagttc tcacaaggtg ataccctagt

2581 attcctgggc cctatggaag gtgggggctt aatatttaag gattggtgca ctagcacatg

2641 ccaatttggt gatcctgggg acattatgag tcctaaagac aaagggttta gctgccctga

2701 cttcacaggc cacttccgga aaaaatgcaa ctttgcaaca acacctgtat gcgagtatga

2761 tggtaatatg gtctctaggt ataagaaagt aatggcaact attgattcct ttcagtcatt

2821 taacactagc tcaattcatt acacagatga aaggattgaa cggaaggacc ctgatgggat

2881 gcttaaggac catctcaata tacttgtcac aaaagacatt gactttgaaa accttgggga

2941 gaacccgtgc aaagtagggc ttcaaacatc atcaatagaa ggtgcatggg gctctggggt

3001 tggtttcacc cttacttgtc aaatctcact gaoagaatgt tctcgctttc tgacatccat

3061 taaagcatgt gacatggcaa tctgttatgg tgcacaaagt gtcacactca ttagaggcca

3121 aaatacagtg aaggtttccg ggaagggtgg gcatagtggc tcttcattca agtgttgtca

3181 agggacagat tgctctcagc aggggctaca agcaagcgca ccacacctag acaaagtcaa

3241 tggaattgtt gaacaagata gtgaaaaagt ctatgatgat ggtgcaccac aatgtggcat

3301 ttcatgctgg tttgttaagt ctggggagtg gataacagga atctttaatg gaaactggat

3361 tgtcattgtt gtgσttgttt tcttcatact atccttaatc ttacttagtc ttttatgccc

3421 cattcgtaag cataagcgct cataagtaaa tactagagaa acctattagc atgtccctat

3481 atatagcctt taacaatgca attttatata tcagtttaaa cttctgtact tattaatttt

3541 ttacatttat taacctagtt atctaaaaaa aataactcct tcattactat aaatcttagt

3601 ccttagtatg tgggtatttc tatatcttgc ggagtctact acta

FIGURE 4 A (SEQ ID NO : 7 ) 8/27

1 MIMWGLLLTM ILIDFGASLR NVYDMKIECP HSINFGESSV TGKVELPPLL LTDAEALVPE 61 SSCNMDNHQS MSIIQKVTKV SWRKKADKAQ AAKDSFETTS SEVNLKGTCT LSHRMVEESY 121 RNRRSVICYD LSCNSTHCKP TMHMIVPVHS CNMMKSCLVG LGPYRIQWY ERTYCTTGIL 181 TEGKCFVPDQ SIVSVIKNGV FDIASVSIVC FFIRVKGTNY KIMASIKTAT ANNCNDTDNK 241 VQGYYLCIVG GNSSPVYAPS TTDFRSMEAL ASLLRAPHGE DHDLSGEEVA TYSIAGQIEG 301 KIPHTANAAN MLFTAFSGIP SYSSLSVFIG SQDGPIIYSP GLFPKLNQSS CDKVALPLIW 361 EGYIDLPGYY ETVHPCNVFC VLSGPGASCE AFSEGGIFNI TSPTCLVSKQ NRFRAAEQQV 421 NFVCQRVDQD IIIYCNGQKK TILTKTLVIG QCIYSVTSLF SIMPGVAHSI AIELCVPGFH 481 GWATAALLTT FCFGWILIPS ITLAVLWLK FFAAILHNSS QENRFKIILR KIKEEFEKTK 541 GSMVCEVCKY ECETGKELKA HNLSCPQSQC PYCFTHCEPT ESAFQAHYKV CQATHRFRDD 601 LKKTITPQST SPGCYRTLNL FRYKSRCYIF TVWVTLLIIE SIMWAAΞASE NVLEPSWNDN 661 AHGVGWPMH TDLELDFSLP SSSKYTYKRK LTSPLNQEQS VDLHIEIESQ GISTSVHALG 721 HWFDGRLNLK TSFHCYGACT KYEYPWHTAK CHFERDFEYE NSWGCNPADC PGIGTGCTAC 781 GLYIDQLKPV GSAYKLITVR YSRKVCVQFG EENLCKTIDM NDCFVTRHVK VCIIGTVSKF 841 SQGDTLVFLG PMEGGGLIFK DWCTSTCQFG DPGDIMSPKD KGFSCPDFTG HFRKKCNFAT 901 TPVCEYDGNM VSRYKKVMAT IDSFQSFNTS SIHYTDERIE RKDPDGMLKD HLNILVTKDI 961 DFENLGENPC KVGLQTSSIK GAWGSGVGFT LTCQISLTEC SRFLTSIKAC DMAICYGAQS 1021 VTLIRGQNTV KVSGKGGHSG SSFKCCQGTD CSQQGLQASA PHLDKVNGIV EQDSEKVYDD 1081 GAPQCGISCW FVKSGEWITG IFNGNWIVIV VLVFFILSLI LLSLLCPIRK HKRS

FIGURE 4B (SEQ ID NO : 8)

9/27

SNV M SEGMENT i tagtagtaga ctccgcacga agaagcaaac actgaataaa ggagatacag aatggtaggg

61 tgggtttgca tcttcctcgt ggtccttact actgcaactg ctgggctaac acggaatctt

121 tatgagttga agatagaatg tccacatact gtgggtttag gtcagggtta cgtgacaggt

181 tcagtggaaa ttacacctat tctcttaacg caggtagctg atctgaagat tgagagttct

241 tgtaatttcg atttgcatgt cccggctacc actacccaaa aatacaatca ggttgactgg

301 accaaaaaaa gttcaactac agaaagcaca aatgcaggtg caactacatt tgaggctaaa

361 acaaaagaga taaatttgaa aggcacatgt aatattcctc caactacatt tgaagctgca

421 tataaatcaa ggaagacagt aatttgttat gatttagcct gtaatcaaac acattgtctt

481 cctacggtcc atttgattgc tcctgttcaa acgtgcatgt ctgtgcggag ctgtatgata

541 ggtttgctgt caagcaggat tcaagtgata tatgagaaga catactgcgt tacaggtcaa

601 ttaatagagg ggctatgttt catcccaaca catacaattg cactcacaca acctggtcat

661 acctatgata ctatgacatt gccagtgact tgttttttag tagctaaaaa gttgggaaca

721 cagcttaagc tggctgttga gttagagaaa ctgattactg gtgtaagttg cacagaaaac

781 agctttcaag gttactacat ctgttttatc gggaaacatt cagagccctt atttgtgcca

841 acaatggagg attataggtc agctgagtta tttacccgta tggttttaaa tccgagaggt

901 gaagatcatg acoctgatca aaatggacaa ggtttaatga gaatagctgg gcctgttaca

961 gctaaggtgc catctacaga aacaactgaa acaatgcaag gaattgcatt tgctggagca

1021 ccaatgtata gctctttctc aaccctcgtg aggaaggctg atcctgagta tgtcttctca

1081 ccaggtataa ttgcagaatc aaatcatagt gtttgtgata aaaaaacagt accccttaca

1141 tggacagggt ttttggoagt ttctggagag atagagaaaa taacaggctg tacagtcttc

1201 tgtacattgg ctggacctgg tgctagttgt gaagcatact cagaaacagg aatctttaat

1261 ataagttctc ctacttgtct agtgaataaa gttcaaaaat tcagaggctc agaacagagg

1321 attaacttca tgtgccaaag agttgatcaa gatgtagttg tctattgtaa tggacaaaag

1381 aaagtcattc ttaccaaaac tctggtcata ggccaatgca tttatacatt cactagttta

1441 ttctcactaa tcccaggagt tgcccattct cttgctgtag agctatgtgt tccaggcctt

1501 catggctggg ctacaacggc attactgatt actttttgct ttggctggct ccttataccg

1561 gcagtcacct taattatact gaagatcctg aggttgctca ctttctcatg ctcacattat

1621 tccacagaat caaaattcaa agttatctta gaaagggtta aggttgaata tcagaaaaca

1681 atgggctcta tggtgtgtga tatttgccac cacgaatgcg aaacagcaaa agaacttgaa

1741 acacataaga aaagctgtcc agaaggtcaa tgcccgtatt gtatgacaat aactgaatcc

1801 actgagagtg ctctccaagc ccattttgca atctgtaagc taacaaacag gtttcaggaa

1861 aacttaaaaa agtcattgaa acgcccagaa gtacggaaag gttgttacag gacactggga

1921 gtttttagat acaagagcag atgttatgtt ggtttagtat ggggaattct tttaacaact

1981 gaactgatca tatgggcagc cagtgcagac acccctttaa tggagtctgg ttggtctgac

2041 acagcacatg gtgtgggcat aattcctatg aagacagatt tggagcttga ttttgcattg

2101 gcctcatcat cttcttacag ttataggcga aagcttgtta atcctgctaa tcaagaagaa

2161 acactccctt ttcatttcca gttagataaa caagtagtgc atgcagagat ccagaaccta

2221 ggacattgga tggatggcac attcaacata aaaactgctt ttcactgtta tggggagtgt

2281 aaaaaatatg cctatccttg gcaaacagcc aagtgtttct ttgaaaagga ttatcaatat

2341 gaaacaagtt ggggctgtaa tccaccagac tgtccagggg taggtacagg ttgtacagct

2401 tgtggggtgt accttgataa gctccgttcg gttgggaaag cgtacaagat agtatcactc

2461 aaatatacac ggaaggtgtg tattcaatta ggaacagaac aaacttgtaa acatatagat

2521 gtaaatgatt gcctggttac cccttctgtc aaagtttgta tgattggtac tatatcaaag

2581 ctccagccag gtgatacctt gttgttctta ggtcctttag agcagggtgg gatoattctt

2641 aagcaatggt gtacaacatc atgtgtgttt ggagatcccg gtgatattat gtcaacaaca

2701 agtgggatgc ggtgcccaga acatactgga tcttttagaa agatctgtgg gtttgctacg

2761 acaccaacat gtgagtatca aggcaacaca gtgtctggat tccaacgcat gatggcaact

2821 cgagattctt tccagtcatt caatgtgaca gaaccacata tcactagcaa ccgacttgag

2881 tggattgatc cagatagcag tatcaaagat cacattaata tggttttaaa tcgagatgtt

2941 tcctttcagg atctaagtga taacccatgc aaggttgacc tgcatacaca atcaattgac

3001 ggggcctggg gttcaggagt aggttttacg ttggtatgta ctgtggggct tacagagtgt

3061 gcaaatttta taacttcaat taaagcatgt gattctgcca tgtgttatgg agccacagtg

3121 acaaatctgc ttagagggtc taacacagtt aaagttgttg gtaaaggtgg gcattctgga

3181 tctttgttta aatgctgcca tgatactgac tgtaccgaag aagggttagc agcatctcca

3241 ccacatttag acagggttac aggctataat caaatagatt ctgataaagt ttatgatgac

3301 ggtgcaccgc cctgtacaat caagtgctgg ttcaccaagt caggtgaatg gctgttggga

3361 atccttaatg gcaattgggt ggtagttgct gttctgattg taattttgat attatcgata

3421 ctccttttta gctttttttg tcctgtcaga agtagaaaga ataaagctaa ttagtgaata

3481 tatatgtgag caagagtatg acaacattat ttcattatat gtatgttctt atatcaataa

3541 catttgtata ttcccataac cgaaatattt atactaattt ttatttttat acaagtatta

3601 actaacccat taacagctaa aaaaaacaaa tccttaacac ctatataatc ccatttgctt

3661 attacgaggc ttttgttcct gcggagcata ctacta

FIGURE 5A (SEQ ID NO: 9) 10/27

1 MVGWVCIFLV VLTTATAGLT RNLYELKIEC PHTVGLGQGY VTGSVEITPI LLTQVADLKI 61 ESSCNFDLHV PATTTQKYNQ VDWTKKSSTT ESTNAGATTF EAKTKEINLK GTCNIPPTTF 121 EAAYKSRKTV ICYDLACNQT HCLPTVHLIA PVQTCMSVRS CMIGLLSSRI QVIYKKTYCV 181 TGQLIEGLCF IPTHTIALTQ PGHTYDTMTL PVTCFLVAKK LGTQLKLAVE LEKLITGVSC 241 TENSFQGYYI CFIGKHSEPL FVPTMEDYRΞ AELFTRMVLN PRGEDHDPDQ NGQGLMRIAG 301 PVTAKVPSTE TTETMQGIAF AGAPMYSSFS TLVRKADPEY VFSPGIIAES NHSVCDKKTV 361 PLTWTGFLAV SGEIEKITGC TVFCTLAGPG ASCEAYSETG IFNISSPTCL VNKVQKFRGS 421 EQRINFMCQR VDQDVWYCN GQKKVILTKT LVIGQCIYTF TSLFSLIPGV AHSLAVELCV 481 PGLHGWATTA LLITFCFGWL LIPAVTLIIL KILRLLTFSC SHYSTESKFK VILERVKVEY 541 QKTMGSMVCD ICHHECKTAK ELETHKKSCP EGQCPYCMTI TESTESALQA HFAICKLTNR 601 FQKNLKKSLK RPEVRKGCYR TLGVFRYKSR CYVGLVWGIL LTTELIIWAA SADTPLMESG 661 WSDTAHGVGI IPMKTDLELD FALASSSSYS YRRKLVNPAN QEETLPFHFQ LDKQWHAEI 721 QNLGHWMDGT FNIKTAFHCY GECKKYAYPW QTAKCFFEKD YQYETSWGCN PPDCPGVGTG 781 CTACGVYLDK LRSVGKAYKI VSLKYTRKVC IQLGTEQTCK HIDVNDCLVT PSVKVCMIGT 841 ISKLQPGDTL LFLGPLEQGG IILKQWCTTS CVFGDPGDIM STTSGMRCPE HTGSFRKICG 901 FATTPTCEYQ GNTVSGFQRM MATRDSFQSF NVTEPHITSN RLEWIDPDSS IKDHINMVLN 961 RDVSFQDLSD NPCKVDLHTQ SIDGAWGSGV GFTLVCTVGL TECANFITSI KACDSAMCYG 1021 ATVTNLLRGS NTVKWGKGG HSGSLFKCCH DTDCTEEGLA ASPPHLDRVT GYNQIDSDKV 1081 YDDGAPPCTI KCWFTKSGEW LLGILNGNWV WAVLIVILI LSILLFSFFC PVRSRKNKAN

FIGURE 5B (SEQ ID NO: 10)

11/27

MTOV M SEGMENT

1 tagtagtaga ctccgcaaga agaagcaaaa aattaaagaa gtgagtttaa aatggaaggg

61 tggtatctgg ttgttcttgg agtctgctat acgctgacac tggcaatgcc caagaccatt

121 tatgagctta aaatggaatg cccgcacact gtgggtctcg gtcaaggtta catcattggc

181 tcaacagaac taggtttgat ctcaattgag gctgcatctg atataaagct cgagagctct

241 tgcaattttg atcttcatac aaσatctatg gcccagaaga gtttcaccca agttgaatgg

301 agaaagaaaa gtgacacaac tgataccaca aatgctgcgt ccactacctt tgaagcacaa

361 actaaaactg ttaaccttag agggacttgt atactggcac ctgaactcta tgatacattg

421 aagaaagtaa aaaagacagt cctgtgctat gatctaacat gtaatcaaac acattgtcag

481 ccaactgtct atctgattgc acctgtattg acatgcatgt caataagaag ttgtatggct

541 agtgtgttta caagcaggat tcaggtgatt tatgaaaaga cacattgtgt aacaggtcag

601 ctgattgagg gtcagtgttt caacccagca oacacattga cattatctca gcctgctcac

661 acttatgata ctgtcaccct tcctatctct tgttttttca caccaaagaa gtcggagcaa

721 ctaaaagtta taaaaacatt tgaaggaatt ctgacgaaga caggttgcac ggagaatgca

781 ttgcagggtt attatgtgtg ttttttaggg agtcattcag aacctttaat tgttccgagt

841 ttggaggaca tacggtctgc tgaagttgtt agtaggatgc ttgtacaccc taggggagaa

901 gaccatgatg ccatacagaa ttcacaaagt cacttaagaa tagtgggacc tatcacagca

961 aaagtgccat caactagttc cacagatacc ctaaagggga cagcctttgc aggcgtccca

1021 atgtatagct ctttatctac actagtcaga aatgcagacc cagaatttgt attttctcca

1081 ggtatagtac ctgaatctaa tcacagtaca tgtgataaga agacagtacc tatcacatgg

1141 acaggctacc taccaatatc aggtgagatg gaaaaagtga ctggatgtac agttttttgt

1201 acactagcag gacctggtgc tagttgtgag gcctattctg aaaatggtat atttaacatc

1261 agttctccaa catgtcttgt aaacaaagtc caaagatttc gtggatctga acagaaaata

1321 aattttatct gtcagcgggt agatcaggat gttgttgtat actgcaatgg gcaaaagaaa

1381 gtcatattaa ccaaaacttt ggttattggg cagtgtattt atacattcac aagcctattt

1441 tcattgatgc ctgatgtagc ccactcattg gctgtagaat tatgtgtccc gggattacat

1501 ggatgggcca ctgtcatgct tctatcaaca ttctgctttg ggtgggtctt gattcctgcg

1561 gtcacattaa taatattaaa gtgtctaagg gttttgacgt tttcttgttc ccattacact

1621 aatgagtcaa aatttaaatt catcctggaa aaagttaaaa ttgaatacca aaagactatg

1681 ggatcaatgg tgtgcgatgt atgtcatcat gagtgtgaaa cagcaaaaga acttgaatca

1741 catagacaga gttgtatcaa tggacaatgt ccttattgca tgacaataac tgaagcaact

1801 gaaagtgcct tgcaagccca ttattccatt tgtaaattga caggaagatt tcaggaggca

1861 ctgaaaaagt cacttaaaaa gccagaggta aaaaaaggtt gttacagaac actcggggta

1921 tttagatata aaagtagatg ttatgtgggt ttggtatggt gcctattgtt gacatgtgaa

1981 attgttattt gggccgcaag tgcagagact ccactaatgg agtcaggctg gtcagatacg

2041 gctoatggtg ttggtgagat tccaatgaag acagacctcg agctggactt ttcactgcct

2101 tcttcatcct cttacagtta taggagaaag ctcacaaacc cagccaataa agaagagtct

2161 attcccttcc acttccagat ggaaaaacaa gtaattcatg ctgaaatcca acccctgggt

2221 cattggatgg atgcgacatt taatattaag actgcatttc attgttatgg tgcatgccag

2281 aaatactctt atccatggca gacatctaag tgcttctttg aaaaggacta ccagtatgaa

2341 acaggctggg gctgtaatcc tggtgactgc ccaggggttg ggactggatg cactgcttgt

2401 ggtgtttatc tcgataaact aaaatctgtt gggaaggcct ataagataat ttctttaaaa

2461 tataccagaa aggtttgtat tcagttagga acagaacaaa cttgcaagca tattgatgca

2521 aatgattgtt tagtgacacc atctgtgaaa gtttgcatag tgggcacagt ttcaaaactt

2581 caaccatctg atactctttt gttcttaggt ccactagaac aagggggaat cattcttaag

2641 caatggtgca caacatcatg tgcatttggg gaccctggtg atatcatgtc cactcccagt

2701 ggtatgaggt gtccagagca cactggatca tttaggaaaa tttgcggttt tgctactaca

2761 ccagtttgtg aatatcaagg aaataccatt tctggatata aaagaatgat ggcaacaaaa

2821 gattcattcc aatcatttaa cttaacagaa cctcacatca caacaaacaa gcttgaatgg

2881 atcgacccag atgggaatac aagagaccac gtaaaccttg tcttaaatag agatgtctca

2941 tttcaggatt taagtgataa cccctgtaaa gtagacctac acacacaagc aatagaaggg

3001 gcatggggtt ctggtgtagg gtttacactc acatgtactg tcggattaac agagtgccca

3061 agttttatga catcaattaa ggcatgtgac ctagctatgt gttatggatc aacagtaaca

3121 aaccttgcca ggggctctaa tacagtgaaa gtagttggta aaggaggcca ttcagggtcc

3181 tcatttaaat gctgtcatga tacagattgc tcctctgaag gtttacttgc atcagoccct

3241 catcttgaga gggtaacagg attcaatcaa attgattcag ataaggttta tgatgatggt

3301 gcaccacctt gcacattcaa atgctggttc actaagtcag gtgagtggct tcttgggatc

3361 ttaaacggga attggattgt tgttgtagtg cttgttgtga tactcattct ctctatcata

3421 atgttcagtg ttttgtgtcc caggagaggg cacaagaaaa ctgtctaagc attgacctca

3481 actcctacat tagatcatat acatttatgc acttcctcat atttagctgc actaagatat

3541 taataaactc tagttattga ctttataaga ttattatgga actaacctca cttaaaaaaa

3601 acaaatactt tactcatata taactccata ttctcttacc gaggcttttg ttcctgcgga

3661 gcatactact a

FIGURE 6 A (SEQ ID NO : 11) 12/27

1 MEGWYLWLG VCYTLTLAMP KTIYELKMEC PHTVGLGQGY IIGSTELGLI SIEAASDIKL 61 ESSCNFDLHT TSMAQKSFTQ VEWRKKSDTT DTTNAASTTF EAQTKTVNLR GTCILAPELY 121 DTLKKVKKTV LCYDLTCNQT HCQPTVYLIA PVLTCMSIRS CMASVFTSRI QVIYEKTHCV 181 TGQLIEGQCF NPAHTLTLSQ PAHTYDTVTL PISCFFTPKK SEQLKVIKTF EGILTKTGCT 241 ENALQGYYVC FLGSHSEPLI VPSLEDIRSA EWSRMLVHP RGEDHDAIQN SQSHLRIVGP 301 ITAKVPSTSS TDTLKGTAFA GVPMYSSLST LVRNADPEFV FSPGIVPESN HSTCDKKTVP 361 ITWTGYLPIS GEMEKVTGCT VFCTLAGPGA SCEAYSENGI FNISSPTCLV NKVQRFRGSE 421 QKINFICQRV DQDWVYCNG QKKVILTKTL VIGQCIYTFT SLFSLMPDVA HSLAVELCVP 481 GLHGWATVML LSTFCFGWVL IPAVTLIILK CLRVLTFSCS HYTNESKFKF ILEKVKIEYQ 541 KTMGSMVCDV CHHECETAKE LESHRQSCIN GQCPYCMTIT EATESALQAH YSICKLTGRF 601 QEALKKSLKK PEVKKGCYRT LGVFRYKSRC YVGLVWCLLL TCEIVIWAAS AETPLMESGW 661 SDTAHGVGEI PMKTDLELDF SLPSSSSYSY RRKLTNPANK EESIPFHFQM EKQVIHAEIQ 721 PLGHWMDATF NIKTAFHCYG ACQKYSYPWQ TSKCFFEKDY QYETGWGCNP GDCPGVGTGC 781 TACGVYLDKL KSVGKAYKII SLKYTRKVCI QLGTEQTCKH IDANDCLVTP SVKVCIVGTV 841 SKLQPSDTLL FLGPLEQGGI ILKQWCTTSC AFGDPGDIMS TPSGMRCPEH TGSFRKICGF 901 ATTPVCEYQG NTISGYKRMM ATKDSFQSFN LTEPHITTNK LEWIDPDGNT RDHVNLVLNR 961 DVSFQDLSDN PCKVDLHTQA IEGAWGSGVG FTLTCTVGLT ECPSFMTSIK ACDLAMCYGS 1021 TVTNLARGSN TVKWGKGGH SGSSFKCCHD TDCSSEGLLA SAPHLERVTG FNQIDSDKVY 1081 DDGAPPCTFK CWFTKSGEWL LGILNGNWIV VWLWILIL SIIMFSVLCP RRGHKKTV

FIGURE 6B (SEQ ID NO: 12)

13/27

HTNV Gl

1 atgagttttg gggaaaacag tgtgataggt tatgtagaat taccccccgt gccattggcc 1 gacacagcac agatggtgcc tgagagttct tgtaacatgg ataatcacca atcgttgaat 1 acaataacaa aatataccca agtaagttgg agaggaaagg ctgatcagtc acagtctagt 1 caaaattcat ttgagacagt gtccactgaa gttgacttga aaggaacatg tgttctaaaa 1 cactaatag

A (SEQ ID NO : 13 )

1 MSFGKNSVIG YVELPPVPLA DTAQMVPESS CNMDNHQSLN TITKYTQVSW RGKADQSQSS 1 QNSFETVSTE VDIIKGTCVLK H

B (SEQ ID NO : 14)

FIGURE 7

PUUV Gl

1 atgagattag ggcagggtct tgttgtgggt tcagtagaat tgccatctct tccaatacag 1 caggtcgaga cactaaagct ggagagttct tgtaattttg atctacatac cagtacagca 1 ggacaacaat cattcacaaa atggacatgg gaaattaaag gtgatcttgc agagaacaca 1 caggcatcat caacaagttt tcaaacaaaa agcagtgaag tgaatttgag aggattatgt 1 ttgatcccta cttaatag

A (SEQ ID NO : 15)

1 MRLGQGLWG SVELPSLPIQ QVETLKLESS CNFDLHTSTA GQQSFTKWTW EIKGDLAENT 1 QASSTSFQTK SSEVNLRGLC LIPT

B (SEQ ID NO : 16 )

FIGURE 8 14/27

SEOV Gl

1 atgaaatttg gggaaacaag tgtgtcaggc tacacagaac tgcccccact ctcattacag

61 gaggcagaac agctggtgcc agagagctca tgcaacatgg acaaccacca atcactctca

121 acaataaata aattaaccaa ggtcatatgg cggaaaaagg caaatcagga atcagcaaac

181 cagaattcat ttgaacttat ggagagtgaa gtcagcttta aagggttgtg tatgttaaag

241 cattaatag

A (SEQ ID NO: 17)

1 MKFGETSVSG YTELPPLSLQ KAEQLVPESS CNMDNHQSLS TINKLTKVIW RKKANQESAN 61 QNSFELMESE VSFKGLCMLK H

B (SEQ ID NO : 18)

FIGURE 9

DOBV Gl

1 atgaactttg gggagagcag tgtaacaggt aaggtggaat taccacccct tctgctcaca

61 gatgcagagg ccttggtccc ggagagttct tgtaacatgg acaaccatca gtctatgtca

121 attatacaaa aagtgacaaa agtgagttgg agaaaaaagg σagacaaagc ccaagctgcc

181 aaggactcat ttgagacaac atcaagcgag gttaatctga aggggacatg cacattgagt

241 cattaatag

A (SEQ ID NO: 19)

1 MNFGESSVTG KVELPPLLLT DAEALVPESS CNMDNHQSMS IIQKVTKVSW RKKADKAQAA 61 KDSFETTSSE VNLKGTCTLS H

B (SEQ ID NO:20)

FIGURE 10 15/27

SNV Gl

1 atgggtttag gtcagggtta cgtgacaggt tcagtggaaa ttacacctat tctcttaacg

61 caggtagctg atctgaagat tgagagttct tgtaatttcg atttgcatgt cccggctacc

121 actacccaaa aatacaatca ggttgactgg accaaaaaaa gttcaactac agaaagcaca

181 aatgcaggtg caactacatt tgaggctaaa acaaaagaga taaatttgaa aggcacatgt

241 aatattcctc cataatag

A (SEQ ID NO : 21)

1 MGLGQGYVTG SVEITPILLT QVADLKIESS CNFDLHVPAT TTQKYNQVDW TKKSSTTEST 61 NAGATTFEAK TKEINLKGTC NIPP

B (SEQ ID NO : 22 )

FIGURE 11

AMDV Gl

1 atgggtctcg gtcaaggtta catcattggc tcaacagaac taggtttgat ctcaattgag

61 gctgcatctg atataaagct cgagagctct tgcaattttg atcttcatac aacatctatg

121 gcccagaaga gtttcaccca agttgaatgg agaaagaaaa gtgacacaac tgataccaca

181 aatgctgcgt ccactacctt tgaagcacaa actaaaactg ttaaccttag agggacttgt

241 atactggcac cttaatag

A (SEQ ID NO : 23 )

1 MGLGQGYIIG STELGLISIE AASDIKLESS CNFDLHTTSM AQKSFTQVEW RKKSDTTDTT 61 NAASTTFEAQ TKTVNLRGTC ILAP

B (SEQ ID NO : 24)

FIGURE 12 16/27

HTNV N

1 atggcaacta tggaggaatt acagagggaa atcaatgccc atgagggtca attagtgata

61 gccaggcaga aggtgaggga tgcagaaaaa cagtatgaaa aggatccaga tgagttgaac

121 aagagaacat taactgaccg agagggcgtt gcagtatcta tccaggcaaa aattgatgag

181 ttaaaaaggc aactggcaga taggattgca actgggaaaa accttgggaa ggaacaagat

241 ccaacagggg tggagcctgg agaccatctg aaagagaggt caatgctcag ttatggtaat

301 gtgctggatt taaaccattt ggatattgat gaacctacag gacagacagc agactggctg

361 agcatcatcg tctatcttac atcctttgtc gtcccgatac ttctgaaagc tctgtatatg

421 ttgacaacaa gggggaggca aactaccaag gataataaag ggacccggat tcgatttaag

481 gatgatagct cgttcgagga tgttaacggt atccggaaac caaaacatct ttacgtgtcc

541 ttgccaaatg cacagtcaag catgaaggca gaagagatta cacctggtag atatagaaca

601 gcagtctgtg ggctctaccc tgcacagatt aaggcacggc agatgatcag tccagttatg

661 agtgtaattg gttttctagc attagcaaag gactggagtg atcgtatcga acaatggtta

721 attgaacctt gcaagcttct tcoagataca gcagcagtta gcctccttgg tggtcctgca

781 acaaacaggg actacttacg gcagcggcaa gtggcattag gcaatatgga gacaaaggag

841 tcaaaggcta tacgccagca tgcagaagca gctggctgta gcatgattga agatattgag

901 tcaccatcat caatatgggt ttttgctgga gcaccagacc gttgtccacc aacatgtttg

961 tttatagcag gtattgctga gcttggggca tttttttcca tcctgcagga catgcgaaat

1021 acaatcatgg catctaagac agttggaaca tctgaggaga agctacggaa gaaatcatca

1081 ttttatcagt cctacctcag aaggacacaa tcaatgggga tacaactagg ccagagaatt

1141 attgtgctct tcatggttgc ctggggaaag gaggctgtgg acaacttcca cttaggggat

1201 gatatggatc ctgagctaag gacactggca cagagcttga ttgatgtcaa agtgaaggaa

1261 atctccaacc aagagccttt gaaactctaa tag

A (SEQ ID NO: 25)

1 MATMEELQRE INAHKGQLVI ARQKVRDAEK QYEKDPDELN KRTLTDREGV AVSIQAKIDE 61 LKRQIiADRIA TGKNLGKEQD PTGVEPGDHL KERSMLSYGN VLDLNHLDID EPTGQTADWL 121 SIIVYLTSFV VPILLKALYM LTTRGRQTTK DNKGTRIRFK DDSSFKDVNG IRKPKHLYVS 181 LPNAQSSMKA EEITPGRYRT AVCGLYPAQI KARQMISPVM SVIGFLALAK DWSDRIEQWL 241 IEPCKLLPDT AAVSLLGGPA TNRDYLRQRQ VALGNMETKE SKAIRQHAEA AGCSMIEDIE 301 SPSSIWVFAG APDRCPPTCL FIAGIAELGA FFSILQDMRN TIMASKTVGT SEEKLRKKSS 361 FYQSYLRRTQ SMGIQLGQRI IVLFMVAWGK EAVDNFHLGD DMDPELRTLA QSLIDVKVKE 421 ISNQEPLKL

B (SEQ ID NO:26)

FIGURE 13 17/27

PUUV N

1 atgagtgact tgacagacat ccaagaggag ataacccgcc atgagcaaca acttgttgtt

Sl gccagacaaa aactcaagga tgcagagaga gcagtggaag tgtacccgga tgacgttaac

121 aagaacacat tacaagcaag acaacaaaca gtgtcagcac tggaggataa actcgcagac

181 tacaagagaa gaatggcaga tgctgtgtcc cggaagaaaa tggatactaa acctactgac

241 ccgactggga ttgaacctga tgatcatαtc aaggagagat caagccttag atatggaaat

301 gtccttgatg tgaatgctat tgacattgaa gaaccaagtg gccagacagc agattggtat

361 actatcggag tctatgtaat agggttcaca attcctatca ttttgaaggc tctatatatg

421 ttgtcaacac gtggaagaca gactgtaaag gaaaacaaag gaacacggat caggttcaag

481 gatgacacat catttgagga tatcaatggc atcaggagac caaaacacct atatgtatcc

541 atgcctactg cccagtccac catgaaagct gaagaactta cacctggacg gttccgtaca

601 atagtatgtg gcttattccc tacacagata caagttcgta acatcatgag tccagtaatg

661 ggagtgattg gtttttcttt cttcgttaaa gactggccag aaaaaattag ggagtttatg

721 gagaaagaat gccctttcat aaagccagaa gttaaacctg ggacaccagc acaggaggta

781 gaatttttga aaagaaatag agtttatttc atgacccgcc aggatgttct tgacaaaaat

841 catgtggctg acatcgataa gttgattgac tatgctgccg αtggtgaccc tacatcgcct

901 gatgacatcg aatctcctaa tgcaccatgg gtatttgctt gtgcaccaga tcggtgcccc

961 ccaacatgta tttatgttgc tgggatggct gaattaggtg cattcttttc catcttacag

1021 gatatgagga acaccattat ggcatctaaa actgtgggca cagcagaaga gaaactgaaa

1081 aagaagtcct ccttctatca atcatatttg cgccgaacac aatcaatggg gattcaactt

1141 gatcagagga taatoctact gtacatgttg gaatggggaa aagaaatggt ggatcatttc

1201 catcttggtg atggcatgga tcctgagcta aggggccttg ctcagtcact catagaccag

1261 aaggtaaaag agatatcaaa ccaagaaccc ttaaagatat gatag

A (SEQ ID NO : 27 )

1 MSDLTDIQEE ITRHEQQLW ARQKLKDAER AVEVYPDDVN KNTLQARQQT VSALEDKLAD 61 YKRRMADAVS RKKMDTKPTD PTGIEPDDHL KERSSLRYGN VLDVNAIDIE EPSGQTADWY 121 TIGVYVIGFT IPI ILKALYM LSTRGRQTVK ENKGTRIRFK DDTSFEDING IRRPKHLYVS 181 MPTAQSTMKA EELTPGRFRT IVCGLFPTQI QVRNIMSPVM GVIGFSFFVK DWPEKIREFM 241 EKECPFIKPE VKPGTPAQEV EFLKRNRVYF MTRQDVLDKN HVADIDKLID YAAAGDPTSP 301 DDIESPNAPW VFACAPDRCP PTCIYVAGMA ELGAFFSILQ DMRNTIMASK TVGTAEEKLK 361 KKSSFYQSYL RRTQSMGIQL DQRIILLYML EWGKEMVDHF HLGDGMDPEL RGLAQSLIDQ 421 KVKEISNQEP LKI

B (SEQ ID NO : 28)

FIGURE 14 18/27

SEOV N

1 atggcaacta tggaggaaat ccagagagaa atcagtgctc acgaggggca gcttgtgata

61 gcacgccaga aggtcaagga tgcagaaaag cagtatgaga aggatcctga tgacttaaac

121 aagagggcac tgcatgatcg ggagagtgtc gcagcttcaa tacaatcaaa aattgatgaa

181 ctgaagcgcc aacttgccga caggattgca gcagggaaga acatcgggca agaccgggat

241 cctacagggg tagagccggg tgatcatctc aaggaaagat cagcactaag ctacgggaat

301 acactggacc tgaatagtct tgacattgat gaacctacag gacaaacagc tgattggctg

361 actataattg tctatctaac atcattcgtg gtcccgatca tcttgaaggc actgtacatg

421 ttaacaacaa gaggtaggca gacttcaaag gacaacaagg ggatgaggat cagattcaag

481 gatgacagct catatgagga tgtcaatggg atcagaaagc ctaaacatct gtatgtgtca

541 atgccaaacg cccaatccag tatgaaggct gaagagataa caccaggaag attccgcact

601 gcagtatgtg ggctatatcc tgcacagata aaggcaagga atatggtaag ccctgtcatg

661 agtgtagttg ggtttttggc actagcaaaa gactggacat ctagaattga agaatggctt

721 ggcgcaccct gcaagttcat ggcagagtct cctattgctg ggagtttatc tgggaatcct

781 gtgaatcgtg actatatcag acaaagacaa ggtgcacttg cagggatgga gccaaaggaa

841 tttcaagccc tcaggcaaca ttcaaaggat gctggatgta cactagttga acatattgag

901 tcaccatcgt oaatatgggt gtttgctggg gcccctgata ggtgtccacc aacatgcttg

961 tttgttggag ggatggctga gttaggtgoc ttcttttcta tacttcagga tatgaggaac

1021 acaatcatgg cttcaaaaac tgtgggcaca gctgatgaaa agcttcgaaa gaaatcatca

1081 ttctatcaat catacctcag acgcacacaa tcaatgggaa tacaactgga ccagaggata

1141 attgttatgt ttatggttgc ctggggaaag gaggcagtgg acaacttcca tctcggtgat

1201 gacatggatc cagagcttcg tagcctggct cagatcttga ttgaccagaa agtgaaggaa

1261 atctcgaacc aggagcctat gaaattataa tag

A (SEQ ID NO : 29 )

1 MATMEEIQRE ISAHEGQLVI ARQKVKDAEK QYEKDPDDLN KRALHDRESV AASIQSKIDE 61 LKRQLADRIA AGKNIGQDRD PTGVEPGDHL KERSALSYGN TLDLNSLDID EPTGQTADWL 121 TIIVYLTSFV VPIILKALYM LTTRGRQTSK DNKGMRIRFK DDSSYEDVNG IRKPKHLYVS 181 MPNAQSSMKA EEITPGRFRT AVCGLYPAQI KARNMVSPVM SWGFLALAK DWTSRIEEWL 241 GAPCKFMAES PIAGSLSGNP VNRDYIRQRQ GALAGMEPKE FQALRQHSKD AGCTLVEHIE 301 SPSSIWVFAG APDRCPPTCL FVGGMAELGA FFSILQDMRN TIMASKTVGT ADEKLRKKSS 361 FYQSYLRRTQ SMGIQLDQRI IVMFMVAWGK EAVDNFHLGD DMDPELRSLA QILIDQKVKE 421 ISNQEPMKL

B (SEQ ID NO: 30)

FIGURE 15 19/27

DOBV N i atggcaacat tagaggaact ccaaaaggaa atcaacaacc atgaaggtca attggtgata

61 gccaggcaga aggtgaagga tgcagaaaag cagtatgaaa aggaccctga cgacctgaat

121 aaaagggcat tgagtgatcg ggaaagcatt gcacaatcaa ttcagggaaa aatcgatgaa

181 ttaaggagac agctggctga tcgtgtggca gcagggaaaa acatcggcaa agaaagggac

241 ccaactgggc tagaccctgg agatcacctc aaagagaagt caatgctcag ttatggaaat

301 gtcattgacc tcaaccatct tgacattgat gaacctacag ggcaaactgc agactggcta

361 agcattgtga tctacctgac atcattcgtg gtcccaatac tgttgaaggc tctttacatg

421 cttaccacca gagggagaca aactactaaa gacaataagg gaatgaggat tcgatttaag

481 gatgacagct cttttgaaga tgtgaatggg attcgaaagc caaagcacct gttcttgtca

541 atgcccaatg cacaatctag tatgaaggca gatgagatta caccaggtcg gttcaggact

601 gcaatctgtg gactataccc agcccaggtt aaggcaagga atttaatcag tcctgtgatg

661 agtgtgattg ggtttgtagc ccttgcaaaa aactggacag aacgggttga agaatggctt

721 gacctcccgt gcaagctact atctgagcca tctccaacgt ctttgaccaa aggcccatcc

781 aocaatcgtg actacttgaa tcaaagacaa ggagcgcttg caaaaatgga aacgaaggaa

841 gctcaggctg tgaggaaaca tgccatagat gctggttgca acctcattga ccatatagac

901 tcaccatcat caatctgggt ctttgcagga gcacctgata gatgccctcc tacctgcctg

961 tttattgcag gcatggcaga gctaggtgca ttctttgctt gcctccagga catgaggaac

1021 accatcatgg catcaaaaac catcggaaca tctgaggaaa agctaaagaa aaagtcatct

1081 ttttaccaat cttacctacg gaggacacaa tctatgggga tacaactgga ccagcgcatc

1141 attgtgcttt ttatggttga ctggggaaaa gaggcagttg atagttttca tctcggtgac

1201 gatatggatc ctgagctccg gcgcctggca caggcattga ttgaccaaaa agtgaaggaa

1261 atatctaatc aggagccgct taagctttaa tag

A (SEQ ID NO : 31)

1 MATLEKLQKE INNHEGQLVI ARQKVKDAEK QYEKDPDDLN KRALSDRESI AQSIQGKIDE 61 LRRQIiADRVA AGKNIGKERD PTGLDPGDHL KEKSMLSYGN VIDLNHLDID EPTGQTADWL 121 SIVIYLTSFV VPILLKALYM LTTRGRQTTK DNKGMRIRFK DDSSFEDVNG IRKPKHLFLS 181 MPNAQSSMKA DEITPGRFRT AICGLYPAQV KARNLISPVM SVIGFVALAK NWTERVEEWL 241 DLPCKLLSEP SPTSLTKGPS TNRDYLNQRQ GALAKMETKE AQAVRKHAID AGCNLIDHID 301 SPSSIWVFAG APDRCPPTCL FIAGMAELGA FFACLQDMRN TIMASKTIGT SEEKLKKKSS 361 FYQSYLRRTQ SMGIQLDQRI IVLFMVDWGK EAVDSFHLGD DMDPELRRLA QALIDQKVKE 421 ISNQEPLKL

B (SEQ ID NO : 32)

FIGURE 16 20/27

SNV N

1 atgagcaccc tcaaagaagt gcaagacaac attactctcc acgaacaaca actcgtgact

61 gocaggcaga agctcaaaga tgcagagaga gcggtggaat tggaccccga tgatgttaac

121 aaaagcacat tacagagcag acgggcagct gtgtctgcat tggagaccaa actcggagaa

181 ctcaagcggg aactggctga tcttattgca gctcagaaat tggcttcaaa acctgttgat

241 ccaacaggga ttgaacctga tgaccattta aaggaaaaat catcactgag atatggaaat

301 gtccttgatg taaattccat tgacctagaa gaaccaagtg ggcaaacagc tgattggaaa

361 tccatcggac tctacattct aagttttgoa ttaccgatta tccttaaagc cttgtacatg

421 ttatctacta gaggccgtca aacaatcaaa gaaaacaagg gaacaagaat tcgatttaag

481 gatgattcat cttatgaaga agtcaatgga atacgtaaac caagacatct atatgtttct

541 atgccaactg ctcagtctac aatgaaagca gatgagatta ctcctgggag gttccgtaca

601 attgcttgtg ggttattccc ggcccaagtc aaagcaagga atattatcag tcctgttgtg

661 ggtgtgattg gctttagttt ctttgtgaaa gattggatgg aaagaattga tgactttctg

721 gctgcaogtt gtccatttct acccgaacag aaagacccta gggatgctgc attggcaact

781 aacagagcct attttataac acgtcaatta caggttgatg agtcaaaggt tagtgatatt

841 gaggatctaa ttgctgatgc aagggctgag tctgccacta tattcgcaga tatcgccact

901 cctcattcag tttgggtctt cgcatgtgct ccagatcgtt gtccacctac agcattatat

961 gtggccggga tgccggagtt gggtgcattt tttgctattc ttcaggatat gaggaacacc

1021 ataatggcat caaaatctgt ggggacatct gaagagaaat tgaagaaaaa atcagcattc

1081 tacoagtcat acttgagacg tactcagtca atggggattc aactggacca gaagataatc

1141 atcttataca tgagccattg gggaagagag gccgtgaatc acttccatct tggagatgat

1201 atggatcttg aacttaggga acttgcccag accctcgtag acatcaaggt cagggagatc

1261 tctaaccaag aaccacttaa actttaatag

A (SEQ ID NO : 33 )

1 MSTLKEVQDN ITLHEQQLVT ARQKLKDAER AVELDPDDVN KSTLQSRRAA VSALETKLGE 61 LKRELADLIA AQKLASKPVD PTGIEPDDHL KEKSSLRYGN VLDVNSIDLE EPSGQTADWK 121 SIGLYILSFA LPIILKALYM LSTRGRQTIK ENKGTRIRFK DDSSYEEVNG IRKPRHLYVS 181 MPTAQSTMKA DEITPGRFRT IACGLFPAQV KARNIISPW GVIGFSFFVK DWMERIDDFL 241 AARCPFLPEQ KDPRDAALAT NRAYFITRQL QVDESKVSDI EDLIADARAE SATIFADIAT 301 PHSVWVFACA PDRCPPTALY VAGMPELGAF FAILQDMRNT IMASKSVGTS EEKLKKKSAF 361 YQSYLRRTQS MGIQLDQKII ILYMSHWGRE AVNHFHLGDD MDLELRELAQ TLVDIKVREI 421 SNQEPLKL

B (SEQ ID NO : 34 )

FIGURE 17 21/27

ANDV N

1 atgagcaccc tccaagaatt gcaggaaaac atcacagcac acgaacaaca gctcgtgact

61 gctcggcaaa agcttaaaga tgccgagaag gcggtggagg tggacccgga tgacgttaac

121 aagagcacac tacaaaatag acgggcagct gtgtctacat tggagaccaa actcggggaa

181 ctcaagagac aacttgcaga tctggtggca gctcaaaaat tggctacaaa accagttgat

241 ccaacagggc ttgagcctga tgaccatctg aaagagaaat catctttgag atatgggaat

301 gtcctggatg ttaactcaat cgatttggaa gaaccgagtg gacagactgc tgattggaag

361 gctataggag catatatctt agggtttgca attccgatca tactaaaagc cctatatatg

421 ctgtcaaccc gtggaagaca gactgtgaaa gacaacaaag gaaccaggat aaggtttaag

481 gatgattctt cctttgaaga ggtcaatggg atacgtaaac cgaaacacct ttatgtctca

541 atgccaactg cacaatctac tatgaaggct gaggaaatta cgccaggacg gtttaggaca

601 attgcttgtg gcctctttcc agcacaggtc aaagctcgaa atataataag tcctgtgatg

661 ggagtaatcg gatttggctt ctttgtgaag gactggatgg atcggataga ggaattcctg

721 gctgcagagt gtccattcct gcctaagcca aaggttgcct cagaagcctt catgtctacc

781 aacaagatgt attttctgaa tagacaaaga caagtcaatg aatctaaggt tcaagacatc

841 attgatttaa tagatcatgc tgaaactgaa tctgctacct tgtttacaga aattgcaaca

901 ccccattcag tctgggtgtt tgcatgtgcg cctgaccggt gccctccgac tgcattgtat

961 gttgcagggg taccagaact tggtgcattc ttttccattc ttcaggacat gcgcaatacc

1021 atcatggcat ccaaatctgt ggggactgca gaagagaagc tgaagaagaa atctgccttt

1081 tatcaatctt acctaagaag gacacaatct atggggattc aactggacca gaaaatcata

1141 attctctaca tgctttcatg gggtaaagaa gctgtgaatc atttccatct tggtgatgat

1201 atggaccctg aactaaggca gctagctcaa tccctgattg acaccaaggt gaaggagatc

1261 tccaaccaag agccacttaa gttgtagtag

A (SEQ ID NO : 35)

1 MSTLQELQEN ITAHEQQLVT ARQKLKDAEK AVEVDPDDVN KSTLQNRRAA VSTLETKLGE 61 LKRQLADLVA AQKLATKPVD PTGLEPDDHL KEKSSLRYGN VLDVNSIDLE EPSGQTADWK 121 AIGAYILGFA IPI ILKALYM LSTRGRQTVK DNKGTRIRFK DDSSFEEVNG IRKPKHLYVS 181 MPTAQSTMKA EEITPGRFRT IACGLFPAQV KARNIISPVM GVIGFGFFVK DWMDRIEEFL 241 AAECPFLPKP KVASEAFMST NKMYFLNRQR QVNESKVQDI IDLIDHAETE SATLFTEIAT 301 PHSVWVFACA PDRCPPTALY VAGVPELGAF FSILQDMRNT IMASKSVGTA EEKLKKKSAF 361 YQSYLRRTQS MGIQLDQKII ILYMLSWGKE AVNHFHLGDD MDPELRQLAQ SLIDTKVKEI 421 SNQEPLKL

B (SEQ ID NO : 36 )

FIGURE 18 22/27

SOD

1 atggctacaa aggctgtttg tgttttgaag ggtgacggcc cagttcaagg tattattaac 1 ttcgagoaga aggaaagtaa tggaccagtg aaggtgtggg gaagcattaa aggactgact 1 gaaggcctgc atggattcca tgttcatgag tttggagata atacagcagg ctgtaccagt 1 gcaggtcctc actttaatcc tctatccgcg ctagccggtg ggccaaagga tgaagagagg 1 catgttggag acttgggcaa tgtgactgct gacaaagatg gtgtggccga tgtgtctatt 1 gaagattctg tgatctcact ctcaggagac cattgcatca ttggccgcac actggtggtc 1 catgaaaaag cagatgactt gggcaaaggt ggaaatgaag aaagtacaaa gacaggaaac 1 gctggaagtc gtttggcttg tggtgtaatt gggatcgccc agaatttgga attcacgcgt 1 caaaacaaa

A (SEQ ID NO: 37)

1 MATKAVCVLK GDGPVQGIIN FEQKESNGPV KVWGSIKGLT EGLHGFHVHE FGDNTAGCTS 1 AGPHFNPLSA LAGGPKDEER HVGDLGNVTA DKDGVADVSI EDSVISLSGD HCIIGRTLW 1 HEKADDLGKG GNEESTKTGN AGSRLACGVI GIAQNLEFTR QNK

B (SEQ ID NO:38)

FIGURE 19

23/27

SOD/HTNV Gl

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG

CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTΆDKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMSFGENSV IGYVELPPVPLADTAQMVPESSCNMDNHQSLNTITKYTQVSWRGKADQSQSSQNSFE TVSTEVDLKGTCVLKH

FIGURE 20 (SEQ ID NO:42)

SOD/PUUV Gl

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMRLGQGLV VGSVELPSLPIQQVETLKLESSCNFDLHTSTAGQQSFTKWTWEIKGDLAENTQASST SFQTKSSEVNLRGLCLIPT

FIGURE 21 (SEQ ID NO: 43)

SOD/SEOV Gl

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMKFGETSV SGYTELPPLSLQEAEQLVPESSCNMDNHQSLSTINKLTKVIWRKKANQESANQNSFE LMESEVSFKGLCMLKH

FIGURE 22 (SEQ ID NO: 44) 24/27

SOD/DOBV Gl

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMNFGESSV TGKVELPPLLLTDAEALVPESSCNMDNHQSMSIIQKVTKVSWRKKADKAQAAKDSFE TTSSEVNLKGTCTLSH

FIGURE 23 (SEQ ID NO: 45)

SOD/SNV Gl

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHC11 GRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMGLGQGYV TGSVEITPILLTQVADLKIESSCNFDLHVPATTTQKYNQVDWTKKSSTTESTNAGAT TFEAKTKEINLKGTCNIPP

FIGURE 24 (SEQ ID NO: 46)

SOD/AHDV Gl

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLVVHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMGLGQGYI IGSTELGLISIEAASDIKLESSCNFDLHTTSMAQKSFTQVEWRKKSDTTDTTNAAST TFEAQTKTVNLRGTCILAP

FIGURE 25 (SEQ ID NO: 47) 25/27

SOD/HTNV N

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMATMEELQ REINAHEGQLVIARQKVRDAEKQYEKDPDELNKRTLTDREGVAVSIQAKIDELKRQL ADRIATGKNLGKEQDPTGVEPGDHLKERSMLSYGNVLDLNHLDIDEPTGQTADWLSI IVYLTSFWPILLKALYMLTTRGRQTTKDNKGTRIRFKDDSSFEDVNGIRKPKHLYV SLPNAQSSMKAEEITPGRYRTAVCGLYPAQIKARQMISPVMSVIGFLALAKDWSDRI EQWLIEPCKLLPDTAAVSLLGGPATNRDYLRQRQVALGNMETKESKAIRQHAEAAGC SMIEDIESPSSIWVFAGAPDRCPPTCLFIAGIAELGAFFSILQDMRNTIMASKTVGT SEEKLRKKSSFYQSYLRRTQSMGIQLGQRIIVLFMVAWGKEAVDNFHLGDDMDPELR TLAQSLIDVKVKEISNQEPLKL

FIGURE 26 (SEQ ID NO: 48)

SOD/PUUV N

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMSDLTDIQ EEITRHEQQLWARQKLKDAERAVEVYPDDVNKNTLQARQQTVSALEDKLADYKRRM ADAVSRKKMDTKPTDPTGIEPDDHLKERSSLRYGNVLDVNAIDIEEPSGQTADWYTI GVYVIGFTIPIILKALYMLSTRGRQTVKENKGTRIRFKDDTSFEDINGIRRPKHLYV SMPTAQSTMKAEELTPGRFRTIVCGLFPTQIQVRNIMSPVMGVIGFSFFVKDWPEKI REFMEKECPFIKPEVKPGTPAQEVEFLKRNRVYFMTRQDVLDKNHVADIDKLIDYAA AGDPTSPDDIESPNAPWVFACAPDRCPPTCIYVAGMAELGAFFSILQDMRNTIMASK TVGTAEEKLKKKSSFYQSYLRRTQSMGIQLDQRIILLYMLEWGKEMVDHFHLGDGMD PELRGLAQSLIDQKVKEISNQEPLKI

FIGURE 27 (SEQ ID NO: 49) 26/27

SOD/SEOV N

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG

CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMATMEEIQ REISAHEGQLVIARQKVKDAEKQYEKDPDDLNKRALHDRESVAASIQSKIDELKRQL ADRIAAGKNIGQDRDPTGVEPGDHLKERSALSYGNTLDLNSLDIDEPTGQTADWLTI IVYLTSFWPIILKALYMLTTRGRQTSKDNKGMRIRFKDDSSYEDVNGIRKPKHLYV SMPNAQSSMKAEEITPGRFRTAVCGLYPAQIKΆRNMVSPVMSWGFLALAKDWTSRI EEWLGAPCKFMAESPIAGSLSGNPVNRDYIRQRQGALAGMEPKEFQALRQHSKDAGC TLVEHIESPSSIWVFAGAPDRCPPTCLFVGGMAELGAFFSILQDMRNTIMASKTVGT ADEKLRKKSSFYQSYLRRTQSMGIQLDQRIIVMFMVAWGKEAVDNFHLGDDMDPELR SLAQILIDQKVKEISNQEPMKL

FIGURE 28 (SEQ ID NO: 50)

SOD/DOBV N

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMATLEELQ KEINNHEGQLVIARQKVKDAEKQYEKDPDDLNKRALSDRESIAQSIQGKIDELRRQL ADRVAAGKNIGKERDPTGLDPGDHLKEKSMLSYGNVIDLNHLDIDEPTGQTADWLSI VIYLTSFWPILLKALYMLTTRGRQTTKDNKGMRIRFKDDSSFEDVNGIRKPKHLFL SMPNAQSSMKADEITPGRFRTAICGLYPAQVKARNLISPVMSVIGFVALAKNWTERV EEWLDLPCKLLSEPSPTSLTKGPSTNRDYLNQRQGALAKMETKEAQAVRKHAIDAGC NLIDHIDSPSSIWVFAGAPDRCPPTCLFIAGMAELGAFFACLQDMRNTIMASKTIGT SEEKLKKKSSFYQSYLRRTQSMGIQLDQRIIVLFMVDWGKEAVDSFHLGDDMDPELR RLAQALIDQKVKEISNQEPLKL

FIGURE 29 (SEQ ID NO: 51) 27/27

SOD/SNV N

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMSTLKEVQ DNITLHEQQLVTARQKLKDAERAVELDPDDVNKSTLQSRRAAVSALETKLGELKREL ADLIAAQKLASKPVDPTGIEPDDHLKEKSSLRYGNVLDVNSIDLEEPSGQTADWKSI GLYILSFALPIILKALYMLSTRGRQTIKENKGTRIRFKDDSSYEEVNGIRKPRHLYV SMPTAQSTMKADEITPGRFRTIACGLFPAQVKARNIISPWGVIGFSFFVKDWMERI DDFLAARCPFLPEQKDPRDAALATNRAYFITRQLQVDESKVSDIEDLIADARAESAT IFADIATPHSVWVFACAPDRCPPTALYVAGMPELGAFFAILQDMRNTIMASKSVGTS

EEKLKKKSAFYQSYLRRTQSMGIQLDQKIIILYMSHWGREAVNHFHLGDDMDLELRE LAQTLVDIKVREISNQEPLKL

FIGURE 30 (SEQ ID NO: 52)

SOD/AMDV N

MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAG CTSAGPHFNPLSALAGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCII GRTLWHEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQNLEFTRQNKMSTLQELQ ENITAHEQQLVTARQKLKDAEKAVEVDPDDVNKSTLQNRRAAVSTLETKLGELKRQL ADLVAAQKLATKPVDPTGLEPDDHLKEKSSLRYGNVLDVNSIDLEEPSGQTADWKAI GAYILGFAIPIILKALYMLSTRGRQTVKDNKGTRIRFKDDSSFEEVNGIRKPKHLYV SMPTAQSTMKAEEITPGRFRTIACGLFPAQVKARNIISPVMGVIGFGFFVKDWMDRI

EEFLAAECPFLPKPKVASEAFMSTNKMYFLNRQRQVNESKVQDIIDLIDHAETESAT LFTEIATPHSVWVFACAPDRCPPTALYVAGVPELGAFFSILQDMRNTIMASKSVGTA EEKLKKKSAFYQSYLRRTQSMGIQLDQKIIILYMLSWGKEAVNHFHLGDDMDPELRQ LAQSLIDTKVKEISNQEPLKL

FIGURE 31 (SEQ ID NO: 53)